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                                           ABSTRACT 
TITLE: Comparison of Esmolol bolus with Esmolol infusion in reducing peri-intubation 
stress response in non cardiac surgical patients:  A randomized controlled trial. 
 DEPARTMENT: Department of Anaesthesiology 
 NAME OF THE CANDIDATE: Ann Sumin Toms 
 DESIGNATION: Post graduate registrar. 
 NAME OF THE GUIDE: Dr. Sathish Kumar Dharmalingam. 
KEY WORDS: Esmolol bolus, Esmolol infusion, Peri intubation stress response 
AIMS OF THE STUDY: 1. To compare the effects of esmolol bolus versus esmolol 
infusion in reducing the stress response to intubation. 2. To identify which mode of 
Esmolol administration (infusion/ bolus) reduces the stress response effectively with the 
least side effects in patients undergoing non cardiac surgery. 
MATERIALS AND METHODS: 92 patients, all of whom were classified under ASA I 
and II and admitted for non cardiac surgery were randomly allocated into 2 groups. The 
esmolol bolus group received 1.5mg/kg of esmolol over 30 seconds 3 minutes prior to 
intubation. The infusion group was given a loading dose of 0.5mg/kg over 30 seconds 
followed by an infusion of 153µg/kg/min for 6.5 minutes and intubated after 2 minutes of 
stopping the infusion. The haemodynamic parameters like heart rate, systolic blood 
pressure, diastolic blood pressure and mean arterial pressure were recorded at the 
baseline, every minute for 2 minutes pre-intubation and every minute for 5 minutes post-
intubation and the values were compared between the two groups. Anaesthesia was 
induced with propofol 2mg/kg, fentanyl 2µg/kg and muscle relaxation attained with 
atracurium 0.5mg/kg supplemented with Isoflurane 2%. 
RESULTS: Analysis of the data showed a significant rise in heart rate in the post 
intubation period with both the groups. Both esmolol bolus and infusion was associated 
with significant pre-intubation and post-intubation hypotension. 
CONCLUSION: The rise in blood pressure following intubation was ablated by both 
esmolol bolus and infusion, but both bolus and infusion failed to effectively prevent the 
heart rate response to intubation. Esmolol infusion has better haemodynamic stability 
than esmolol bolus.  
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 INTRODUCTION 
 
Anaesthetizing a patient by giving general anaesthesia requires special attention with 
regards to maintaining the airway. Intubating the patient using an endotracheal tube is 
one of the most favored methods of providing general anaesthesia. It helps in maintaining 
the airway, providing anaesthetizing gases and for ensuring oxygen delivery along with 
carbon dioxide removal. However, intubating the patient with an endotracheal tube is not 
devoid of ill effects.  
Direct laryngoscopy and endotracheal intubation frequently causes a cardiovascular stress 
response characterized by hypertension and tachycardia due to reflex sympathetic 
stimulation. This response is transient and lasts for less than 10 minutes. It may be well 
tolerated by a healthy individual but may become hazardous in patients with 
hypertension, diabetes mellitus, coronary artery disease (CAD), cerebrovascular disease 
or thyrotoxicosis.(1)   
Numerous agents like opioids, calcium channel blockers, beta blockers, magnesium 
sulphate, local anaesthetics etc have been used to blunt the hemodynamic response to 
laryngoscopy and intubation. Among the various beta blockers, Esmolol is an attractive 
option because of its cardio selectivity and ultra-short duration of action.(1) However, 
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there are only two ways by which Esmolol can be administered, either as a bolus or as an 
infusion. Although both modes of Esmolol administration have been found to be effective  
in decreasing the stress response, studies comparing these two methods have been rare.  
Here we propose to compare the efficacy of beta blockade with Esmolol bolus versus 
Esmolol infusion (with loading dose) in reducing the stress response with minimal side 
effects. 
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 AIMS OF THE STUDY 
 
Primary aim  
 
To compare the effects of esmolol bolus versus esmolol infusion in reducing the stress 
response to intubation. 
  
 
Secondary aim 
 
To identify which mode of Esmolol administration (infusion/ bolus) reduces the stress 
response effectively with the least side effects in patients undergoing non cardiac surgery. 
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REVIEW OF LITERATURE 
 
GENERAL ANAESTHESIA 
General anaesthesia means completely anaesthetizing the individual in order to provide 
analgesia, amnesia and muscle relaxation. The induction of anaesthesia is by a 
combination of drugs which include analgesics like injection fentanyl 1-2 microgram/kg, 
induction agents like injection propofol 2-2.5mg/kg or injection thiopentone the dose of 
which varies with the age of the individual. The usually used adult dose of thiopentone is 
4-5 mg/kg. Commonly used intravenous induction agents are injection ketamine and 
injection etomidate. The drugs used for induction depends upon the patient characteristics 
and the type of surgery.  
If an endotracheal intubation is planned, a muscle relaxant usually follows the 
administration of the induction agent. It can either be a depolarizing agent like injection 
succinyl choline 2 mg/kg or non-depolarizing agents like injection atracurium 0.5mg/kg, 
injection vecuronium 0.1-0.15 mg/kg or injection rocuronium 1mg/kg. Endotracheal 
intubation is accomplished at a minute after administration of succinyl choline and 
rocuronium or at 3 minutes following administration of other muscle relaxants. The 
endotracheal tube is then secured after confirming its correct position.  
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Agents that decrease the stress response to intubation is either given 3 minutes prior to 
endotracheal intubation or is timed based on the peak onset of action of the drug. 
Anaesthesia is maintained with air/nitrous oxide, oxygen, inhalational agents and top ups 
of muscle relaxant as and when required. 
  
METHOD OF ENDOTRACHEAL INTUBATION BY DIRECT LARYNGOSCOPY 
 
 
Fig.1: Method of endotracheal intubation by direct laryngoscopy. 
 
The first endotracheal intubation was probably performed by Andreas Vesalius, an 
anatomist in 1543.(2) William Macewen performed the first orotracheal intubation for 
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providing anaesthesia in 1878.(3) The first direct laryngoscopy was described by Alfred 
Kirstein in 1895.(4) However the credit for popularizing endotracheal intubation rests 
with Edar Rowbotham and Ivan Magill.(5) 
The mechanism of endotracheal intubation includes proper positioning of the patient, 
direct laryngoscopy and insertion of an appropriately sized endotracheal tube. The patient 
has to be placed in a Magill position which is flexion at the lower cervical vertebra with 
extension at the atlanto-occipital joint. In the supine position, the oral and pharyngeal 
axes are perpendicular to each other. Atlanto-occipital extension helps in aligning the oral 
and pharyngeal axis while flexion of lower cervical vertebra causes the pharyngeal and 
laryngeal axis to align. In the case of obese patients, ramping is used inorder to bring the 
oropharyngeal axis in the same plane, wherein the ear lobule and the sternum will be 
placed at the same level. After fixing the head in this position, the mouth is opened and 
the laryngoscope is inserted through the side of the mouth. Using the blade of the 
laryngoscope the tongue is pushed to one side and the blade of scope is brought to the 
centre. The tip of the laryngoscope blade is then advanced to the vallecula in the case of a 
curved blade, or beneath the epiglottis in the case of a straight blade. Then pressure is 
applied to the tip of the blade, in order to lift the epiglottis anteriorly and visualize the 
glottic opening for inserting the endotracheal tube.(6) 
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Fig.2: Position for endotracheal intubation. 
 
STRESS RESPONSE TO INTUBATION  
Laryngoscopy and endotracheal intubation can alter the haemodynamics of a patient. The 
first description on the stress response to intubation was given by Reid and Brace.(7) The 
stress response usually results in sympathetic stimulation, which manifests as an increase 
in heart rate and blood pressure. Activation of the parasympathetic system can lead to 
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bradycardia, coughing and bronchoconstriction. These sympathetic and parasympathetic 
responses to intubation are mediated by the glossopharyngeal and vagus nerves.(8)  
 
 
Fig.3: Response to various types of stress in the body. 
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PATHWAY OF STRESS RESPONSE TO INTUBATION 
 
NERVE SUPPLY OF PHARYNX  
Sensory supply to the posterior one third of tongue, the fauces, the tonsils, the anterior 
epiglottis and the whole of pharynx is by the glossopharyngeal nerve.  
Motor supply is provided by the vagus nerve. 
 
NERVE SUPPLY OF LARYNX 
Sensory supply: The internal laryngeal nerve which is a branch of superior laryngeal 
nerve which in turn is a branch of vagus provides sensory supply to the posterior part of 
epiglottis till the level of the vocal cords. The recurrent laryngeal nerve which is a direct 
branch of the vagus provides sensory supply to the laryngeal mucosa below the level of 
the vocal cords. 
Motor supply:  All the intrinsic muscles of larynx except the cricothyroid are supplied by 
the recurrent laryngeal nerve. The external laryngeal nerve which is a branch of the 
superior laryngeal nerve supplies the cricothyroid muscle.(9)  
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ANATOMY OF THE PHARYNX AND LARYNX 
 
Fig.4: Anatomy of the pharynx and larynx. 
 
REFLEX PATHWAY OF STRESS RESPONSE TO INTUBATION 
The sensory information from the hard palate, upper part of the oropharynx, posterior 
most part of the tongue, lower part of the oropharynx, larynx and trachea are carried by 
the glossopharyngeal and the vagus nerves. The afferents from these two sensory nerves 
terminate in the nucleus tractus solitarius.  
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The fibers from nucleus tractus solitarius terminate mainly in the parabrachial nucleus, 
which thus becomes the main relay station. The parabrachial nucleus has a minimum of 
thirteen separate sub-nuclei which projects extensively to many areas of the brainstem, 
basal forebrain, hypothalamus, cerebral cortex and thalamus. These brain structures are 
also innervated by direct projections from the nucleus tractus solitarius.  
The principal sites for the integration of function of the autonomic nervous system are the 
hypothalamus and the nucleus tractus solitarius. It includes regulation of fat and 
carbohydrate metabolism, water balance, body temperature, emotions, blood pressure, 
respiration, sleep and reproduction. Stimulation of the hypothalamus and nucleus tractus 
solitarius results in release of hormones and activation of the bulbospinal pathways, 
which in turn mediates motor and autonomic responses.(10) 
 
PHASES OF STRESS RESPONSE TO INTUBATION 
Stress response to intubation can be divided into two phases. Phase one occurs during 
laryngoscopy due to stretching of the pharyngeal muscles. Phase two occurs due to 
stretching of the laryngeal muscles following insertion of the endotracheal tube into the 
trachea and its inflation. Both phases are associated with stress response but it has been 
found to be greater in phase two as compared to phase one.(11) 
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MANIFESTATION OF STRESS RESPONSE TO INTUBATION 
Ever since the first description of haemodynamic disturbance occurring due to 
laryngoscopy and endotracheal intubation was given by Reid and Brace in 1940(7), many 
other studies have been carried out describing the same. A study by Burstein et al have 
shown that endotracheal intubation is accompanied by ECG changes in as much as 68% 
of the cases.(12) King et al described in his study that insertion of an endotracheal tube 
into the trachea augments the haemodynamic stress response caused by laryngoscopy, in 
addition to producing cardiac arrhythmias.(13)  
Stress response to laryngoscopy and endotracheal intubation may manifest as a 
sympathetic or a parasympathetic response.(8) The sympathetic response raises the 
plasma catecholamine levels, with a subsequent increase in heart rate and blood pressure. 
Direct laryngoscopy and endotracheal intubation can result in an average of 40-50% 
increase in blood pressure and about 20% increase in heart rate. (14) This increase in 
heart rate and blood pressure in turn can cause myocardial ischemia, myocardial 
infarction, cardiac arrhythmias, acute heart failure, pulmonary oedema and raised 
intracranial pressure. The raised intracranial pressure can be hazardous in patients with 
intracranial tumours and cerebral aneurysms. It can even cause rupture of an intracranial 
aneurysm.(15,16).  
Endotracheal intubation can also cause a rise in intraocular pressure.(17) Increased 
activity of the sympathetic nervous system in hypertensive patients (15) results in them  
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showing an exaggerated and unpredictable sympathetic response to laryngoscopy.(16) 
The haemodynamic response to intubation is maintained at a high level in patients with 
both treated and untreated hypertension.(18) The activation of the parasympathetic 
system can lead on to bradycardia, coughing and bronchoconstriction.(8) This stress 
response to endotracheal intubation is a transient one which  starts with laryngoscopy and 
lasts for about 5-10 minutes following intubation.(15)  
Direct laryngoscopy and tracheal intubation is considered as the most critical event in the 
administration of general anaesthesia due to its propensity to produce a marked but 
transient sympatho-adrenal response.(19) 
 
 
FACTORS AFFECTING STRESS RESPONSE TO INTUBATION 
a. Duration of laryngoscopy:  
The stress response to intubation increases with the duration of laryngoscopy.(20) The 
magnitude and duration of the haemodynamic changes will be less if the duration of 
laryngoscopy is kept to less than 15 seconds.  
b. Plane of anaesthesia:  
Intubation response will be more if the plane of anaesthesia is light.(21, 22) 
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c. Number of intubation attempts: 
Repeated  intubation attempts causes the stress response to increase.(16) 
d. Type of intubation equipment: 
Recent advances in the field of anaesthesia have resulted in the invention of new 
equipments and in the modification of older equipments. This has made intubation easy 
even under trying circumstances. Many studies have been carried out to find whether 
there is a difference in stress response to intubation with the use of these newer 
equipments. 
Haidry et al compared the stress response to intubation with McCoy and Macintosh 
laryngoscopes. The changes in heart rate, systolic blood pressure, diastolic blood pressure 
and mean arterial blood pressure were compared for 10 minutes after intubation. They 
concluded that the haemodynamic changes were of a shorter duration and of a lesser 
magnitude with McCoy laryngoscope when compared to Macintosh laryngoscope.(23) 
Ghoneim et al compared between Bonfils intubation endoscope and Macintosh 
laryngoscope. Based on the changes in heart rate, mean arterial pressure, blood 
catecholamine levels and intra-ocular pressure in the post intubation period they 
concluded that Bonfils endoscope is associated with less haemodynamic instability than 
with Macintosh laryngoscope.(24) 
Kitamura et al compared the haemodynamic effects of intubation with a Styletscope and 
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 a Macintosh laryngoscope. Based on the heart rate and blood pressure changes following 
intubation it was concluded that haemodynamic stability was better with a Styletscope 
than with a Macintosh laryngoscope.(25) 
Similarly various other studies were conducted to compare the stress response to 
intubation with regards to different anaesthesia equipments. Siddiqui NT et al in their 
study on ASA I and ASA II patients found that intubation through a intubating laryngeal 
mask airway was associated with a lesser degree of stress response as opposed to using a 
Macintosh laryngoscope.(26)  
Sener EB et al compared the hemodynamic responses following tracheal intubation with 
conventional laryngoscopy and intubating laryngeal mask airway in hypertensive 
patients. Measurement of systolic blood pressure, diastolic blood pressures, heart rate, 
rate pressure product and ST segment changes were made at baseline, pre intubation, and 
every minute for the first 5 minutes following intubation. The duration of intubation, 
number of intubation attempts, and the airway complications were also recorded. The 
intubation time was seen to be less in the conventional laryngoscopy group as compared 
to the intubating laryngeal mask airway group. The systolic blood pressure, diastolic 
blood pressure and the rate pressure product were found to be higher in the intubating 
laryngeal mask airway group as compared to those in the conventional laryngoscopy 
group at 1 and 2 minutes following intubation. There were no differences in the ST 
segment changes between the two groups.  
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Repeated and intensive oropharyngeal and tracheal stimulation from an intubating 
laryngeal mask airway induces a greater pressor response when compared to 
conventional laryngoscopy in hypertensive patients. Hence they concluded that 
conventional laryngoscopy, which is rapid and safe to perform, may be preferred in 
hypertensive patients with normal airways.(16) Various studies have also concluded that 
there is no difference in the intubation response between glidescope, video laryngoscope 
and direct laryngoscope.(27) 
e. Skill of the anaesthesiololgist:  
Duration of laryngoscopy and failed attempts are less with a trained anaesthesiologist and 
thereby the stress response. 
f. Co-morbidity  
Intubation response has been found to be exaggerated in hypertensive patients.(16) 
Various attempts have been made from time to time to decrease or eliminate the 
sympathetic response to laryngoscopy and endotracheal intubation. Rosenberg and Kuhn 
used cocaine as a local anaesthetic to prevent the cough reflex during endotracheal 
intubation.(3) Intravenous injection of procaine prior to endotracheal intubation was 
found to be worthwhile by some.(28) Adrenergic agents like phentolamine have also 
been employed to reduce the stress response. It has been shown that 5mg doses of  
phentolamine effectively obtunds the laryngoscopic response to endotracheal 
intubation.(29) 
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Durrani et al compared the effects of preservative free chloroprocaine 4.5mg/kg and 
lignocaine 1.5mg/kg given intravenously 45 seconds prior to endotracheal intubation. It 
was seen that chloroprocaine effectively blunted the stress response to laryngoscopy and 
intubation and had a better haemodynamic stability than 1.5 mg/kg lignocaine.(30) 
 
DRUGS USED IN THE ABLATION OF STRESS RESPONSE TO 
INTUBATION 
 A short duration smooth laryngoscopy of less than 15 second duration is the most 
effective way of decreasing the stress response. 
 Lignocaine. 
 
Fig.5: Structure of Lignocaine. 
Lignocaine is an amide based local anaesthetic. It acts by selectively binding to sodium 
channels in its inactive closed state, thereby preventing its change into the activated open 
state, and thus causing a conduction blockade for nerve impulses. Of the various 
preparations available, 2% preservative free lignocaine 1.5 mg/kg is used intravenously 
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90 seconds before tracheal intubation to decrease the stress response associated with 
intubation.  
Lignocaine has a property of increasing the cerebrovascular resistance and thus reducing 
the cerebral blood flow. This helps in preventing the rise of intracranial pressure that 
occurs during intubation. In addition, its anti-tussive property while decreasing the reflex 
induced bronchospasm also accounts for ablation of stress response during intubation. 
Though effective in decreasing the systemic vascular resistance, it has been found to be 
ineffective in reducing the heart rate in response to intubation.(31)  
In a study, Tajne et al compared magnesium sulphafe 50mg/kg given one minute before 
the induction of anaesthesia with lignocaine 1.5 mg/kg given 90 seconds before induction 
in decreasing the haemodynamic response to intubation. He concluded that lignocaine 
was better in reducing the intubation response whereas magnesium sulphate ablated the 
hypertensive response alone to laryngoscopy and intubation.(32) 
You Mi Ki et al studied the effects of topical lignocaine 4% and 10% sprayed into the 
larynx after laryngoscopy but before intubation and the subsequent haemodynamic 
changes that occurred in children aged 2-16 years. They concluded in their study that 
topical  lignocaine spray into the larynx despite the concentration, was ineffective in 
suppressing the stress response.(33) 
Abou M Adi et al compared the effects of different doses of lignocaine- 0.75mg/kg and 
1.5mg/kg in blunting the stress response to intubation. It was shown in his study that low 
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dose lignocaine was ineffective in attenuating the stress response to intubation whereas 
lignocaine 1.5mg/kg offered borderline protection against post intubation tachycardia and 
hypertension.(34) 
Venus et al tried topical anaesthesia of the oropharynx with 6ml of 4% lignocaine for 
attenuation of stress response to intubation and concluded that lignocaine aerosolization 
successfully prevented the increase in heart rate and arterial pressure following 
endotracheal intubation.(35) 
 
 Fentanyl 
 
Fig.:6: Structure of Fentanyl. 
Fentanyl is a synthetic opioid agonist. It has a rapid onset of action in 1 to 2 minutes and 
the peak effect is attained in 3 to 5 minutes.It has a short duration of action of 30-60 
minutes. After intravenous administration rapid re-distribution of the drug occurs to 
inactive tissue sites like skeletal muscle, adipose tissue and lungs. The pKa of fentanyl is 
8.4. It is 79%- 87% protein bound. Fentanyl is used for ablation of stress response as an 
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adjuvant to inhalational anaesthetics during intubation at a dose of 2 to 20 microgram per 
kilogram intravenously. It can also be used for opioid induction of anaesthesia, for 
premedication as well as intra-operative and post-operative analgesia.  
The advantages of using fentanyl as an induction agent include absence of direct 
myocardial depression, lack of histamine release and ablation of the stress response to 
intubation and surgery. The disadvantage of fentanyl induction is that, even at any dose it 
cannot prevent the sympathetic response to a painful surgical stimulus. It is also said to 
cause intra operative patient awareness. The other concern regarding the use of high dose 
fentanyl for induction of anaesthesia is the possibility of post operative ventilatory 
depression. 
The common side effects include bradycardia, chest rigidity, seizures on rapid 
intravenous administration, a modest rise in intracranial pressure and post operative 
respiratory depression. (31) 
Hosalli et al compared the efficacy of different doses of fentanyl in decreasing the stress 
response to laryngoscopy and endotracheal intubation. They compared fentanyl 3µ/kg 
with fentanyl 5µ/kg given 3 minutes before endotracheal intubation in ASA 1 and ASA II 
patients. They concluded  that fentanyl 5µg/kg gave better haemodynamic stability when 
compared to fentanyl 3µ/kg.(36)  
Hassani et al compared the effects of fentanyl 2µ/kg with fentanyl 2µg/kg and lignocaine 
1.5mg/kg given intravenously 3 minutes before endotracheal intubation in decreasing the 
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stress response. They found that both fentanyl alone and fentanyl given along with 
lignocaine could effectively blunt the intubation response to endotracheal intubation. 
Fentanyl along with lignocaine did not provide any added advantage over fentanyl alone 
in decreasing the stress response.(37)  
Mireskandari et al compared the efficacy of different opioids in attenuating the 
haemodynamic response to intubation in ASA I and II paediatric patients aging from 1 to 
6 years. They compared between intravenous fentanyl 1µ/kg, alfentanil 10µg/kg, 
sufentanil 0.1µg/kg and remifentanil 1µg/kg. The study drug was given before induction 
of anaesthesia. Anaesthesia was induced with propofol 2.5mg/kg, and the muscle 
relaxation achieved with cisatracurium 0.2mg/kg. Endotracheal intubation was done 3 
minutes after induction of anaesthesia. It was concluded that intravenous fentanyl 
achieved better haemodynamic stability when compared to intravenous remifentanil, 
sufentanil or alfentanil in the above mentioned doses.(38) 
Sufentanil 
 
Fig.7: Structure of Sufentanil. 
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Sufentanil is a highly potent µ opioid receptor agonist. It has a rapid onset of action with 
peak effect in 3-5 minutes. It is highly protein bound, at about 93% and this contributes to 
its small volume of distribution. In the body, it is mainly bound to alpha one acid 
glycoprotein and is metabolized in the liver by N-dealkylation and O-demethylation. The 
by-product des-methyl sufentanil has 10% activity of the parent compound and is 
excreted by the kidneys.  
It can be used in opioid induction, as an adjunct to total intravenous anaesthesia, to 
decrease the stress response to intubation and labour analgesia. The complications of 
sufentanil include bradycardia, rigidity of the chest and abdomen, seizures on rapid 
intravenous administration and a moderate increase in the intracranial pressure in head 
injury patients in addition to other opioid side effects. The chest wall rigidity may make 
ventilation difficult which can be overcome by endotracheal intubation.(31) 
Xue et al in his study has compared the effects of intravenous sufentanil at various doses 
namely 0.1µg/kg, 0.2µg/kg and 0.3µg/kg given 5 minutes before endotracheal intubation 
along with propofol induction in decreasing the stress response to intubation in paediatric 
population. They concluded that sufentanil at 0.3µg/kg was most effective in completely 
abolishing the cardiovascular responses to intubation(39) .  
Zsigmond EK et al studied the effects of neuroleptanalgesia with midazolam and fentanyl 
in decreasing the stress response to tracheal intubation in adult patients undergoing 
coronary artery surgery. Midazolam was given at a dose of 0.14 +/- 0.01mg/kg over one 
minute followed by sufentanil 1.5µg/kg 5 minutes later. A total of 4-5µg/kg of sufentanil 
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was given in incremental doses over 10 minutes before tracheal intubation. Pancuronium 
0.1mg/kg was given one minute after the initial dose of sufentanil for providing muscle 
relaxation. No adverse haemodynamic response or increase in catecholamine levels were 
seen following tracheal intubation.(40) 
 
Remifentanyl 
 
Fig.8: Structure of Remifentanyl. 
Remifentanil is a µ opioid receptor agonist. It has a rapid onset of action with peak effect 
in 3 to 5 minutes.(41) It has a unique structure due to its ester linkage. Steady state 
plasma concentration is reached 10 minutes after starting an infusion. As a result of rapid 
clearance and rapid achievement of blood brain equilibration, a change in the rate of 
infusion will cause immediate changes in the effects produced. The elimination half time 
for remifentanil is 6.3 minutes. Context sensitive half time for remifentanil is 4 minutes 
and is not dependent on the duration of infusion of the drug. 
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Its ester linkage makes it susceptible to metabolism by non specific tissue and plasma 
esterases. As a result of this esterase metabolism it has a rapid and precise titratable 
effect, rapid onset and offset of action, and no cumulative effect. The pharmacokinetics 
of remifentanil is usually not changed in renal or hepatic failure, as the esterases are 
preserved in these conditions. 
Remifentanil is used for providing intra operative and post operative analgesia, induction 
of anaesthesia along with a hypnotic and to decrease the stress response to laryngoscopy 
and intubation. The side effects include vomiting, nausea, depression of ventilation, 
minimal decrease in heart rate and blood pressure, skeletal muscle rigidity on rapid 
intravenous injection of large bolus doses. (31) 
O’Hare et al compared the efficacy of using different bolus doses of remifentanil 0.5µ/kg, 
1µg/kg and 1.5µg/kg given over 30 seconds in patients undergoing rapid sequence 
induction of anaesthesia and noting whether there is a definite reduction of stress 
response to intubation. They found that 0.5µg/kg was ineffective in blunting the 
intubation response where as remifentanil at 1.5µg/kg was associated with hypotension. 
Remifentanil at 1µg/kg abolished the stress response to intubation, albeit with a small 
increase in diastolic blood pressure.(42) 
McAtamney et al compared the effects of remifentanil 0.25µg/kg, 0.5µg/kg and 1µg/kg 
to decrease stress response to intubation in ASA I and ASA II patients. The study drug 
was given as a bolus over 30 seconds 1 minute prior to intubation. They concluded that 
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when compared to remifentanil 0.25µg/kg and 0.5µg/kg, remifentanil 1µg/kg was more 
effective in decreasing the haemodynamic response to intubation.(43) 
Alfentanil 
 
Fig.9: Structure of Alfentanyl. 
Alfentanil is a fentanyl analogue which is less potent and with a shorter duration of action 
as compared to fentanyl. It has a rapid onset of action after intravenous administration 
when compared to sufentanil and fentanyl. It has a pKa of 6.5 and is 92% protein bound. 
Alfentanil is mainly bound to the protein alpha one acid glycoprotein. At a pH of 7.4 
nearly 90% of the drug exists in the non ionized form. It crosses the placenta as well as 
the blood brain barrier. Alfentanil is metabolized in the liver. There is no change in the 
clearance or elimination half time of alfentanil in renal failure. Almost 96% of the drug is 
eliminated from the circulation within one hour of its administration. 
Alfentanil at 15 microgram per kilogram given intravenously 90 seconds prior to direct 
laryngoscopy can decrease the heart rate and blood pressure response to intubation and 
laryngoscopy. 
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Alfentanil like other opioids can cause respiratory depression, pruritus etc. It also 
increases the pressure in the biliary tract and has the potential for producing acute 
dystonia in untreated Parkinsons’ patients. (31) 
Miller et al studied the efficacy of varying bolus doses of alfentanil 15µg/kg, 30µg/kg 
and 45µg/kg in reducing the haemodynamic stress response to intubation. Alfentanil was 
administered before the induction of anaesthesia and tracheal intubation done, a minute 
after the induction of anaesthesia. It was noticed that a dose dependent reduction in 
catecholamine response was seen till a dose of 30µg/kg of alfentanil was reached. Any 
further increase in dose did not provide additional advantage.(44) 
Martineau et al studied the effects of bolus dose alfentanil 30µg/kg, 45µg/kg and 60µg/kg 
in reducing the haemodynamic response to rapid-sequence induction of anaesthesia. After 
administration of the study drug anaesthesia was induced with thiopentone 4 mg/kg and 
succinyl choline 1.5mg/kg. Trachea was intubated one minute after induction. It was 
concluded that alfentanil 30µg/kg effectively reduced the tachycardia and hypertensive 
response to intubation without causing much haemodynamic instability whereas higher 
doses of alfentanil was associated with a significant but transient decrease in heart rate 
and mean arterial blood pressure.(45)   
Clonidine   
Clonidine is a centrally acting sympatholytic with a greater affinity for alpha 2 receptors 
as compared to alpha 1. The major haemodynamic changes results from the stimulation 
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of α2A receptors in the medulla. This results in decreased sympathetic nervous system 
outflow to peripheral tissues from the central nervous system causing a decrease in heart 
rate, systemic blood pressure and cardiac output. Clonidine is used as an antihypertensive 
agent, as an analgesic, for treatment of opioid withdrawal, for abatement of shivering, for 
premedication and for attenuating of the haemodynamic response to laryngoscopy and 
intubation.  Clonidine is used orally or intravenously to decrease the stress response to 
intubation. While the peak effect of intravenous clonidine is obtained within 10 minutes, 
it takes about 60-90 minutes for oral clonidine. The most common side effects of 
clonidine are xerostomia, sedation and rebound hypertension.(31,46) 
 
Fig.10: Structure of Clonidine. 
Arora et al compared the effects of intravenous clonidine 1µg/kg and 2µg/kg given 10 
minutes before induction of anaesthesia in reducing the stress response to laryngoscopy 
and endotracheal intubation. While fentanyl 2µg/kg/ propofol 1 to 1.5 mg/kg was used 
for induction of anaesthesia, muscle relaxation was provided for by atracurium 0.6mg/kg. 
Endotracheal intubation was performed 3 minutes after induction. It was concluded that a 
single intravenous bolus dose of clonidine 1µg/kg with fentanyl 2µg/kg is a safe method 
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to decrease the stress response to laryngoscopy without much haemodynamic 
disturbances. Clonidine 2µg/kg was associated with hypotension at the time of induction 
and post operative sedation.(47)  
Sameenakousar et al compared intravenous clonidine 2µg/kg with fentanyl 2µg/kg given 
over 30 seconds 5 minutes before laryngoscopy. Anaesthesia was induced with 
thiopentone 5mg/kg and succinyl choline 2mg/kg. They concluded that intravenous 
clonidine  2µg/kg was better than fentanyl 2µg/kg  in reducing the stress response to 
laryngoscopy and intubation.(48) 
Zalunardo et al compared the efficacy of intravenous clonidine 3µg/kg given immediately 
before induction and oral clonidine 4µg/kg given 90 minutes prior to induction in 
decreasing the catecholamine response to endotracheal intubation. They concluded that 
intravenous clonidine gave much better haemodynamic stability to endotracheal 
intubation than oral clonidine.(49) 
Dexmedetomidine. 
Dexmedetomidine is a potent alpha 2 receptor agonist with 1600 times more selective 
action than alpha 1. The onset of action of dexmedetomidine is within 5 minutes and peak 
effect is seen in 15 minutes. It is available as a parenteral formula. It is 94% protein 
bound and the elimination half time of dexmedetomidine is 2 to 3 hours. 
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Fig.11: Structure of Dexmedetomidine. 
Dexmedetomidine provides sedation, anxiolysis, hypnosis, analgesia and sympatholysis. 
It decreases intraocular pressure, catacholamine release and peri operative analgesic 
requirement. It is also useful in decreasing the stress response to intubation and 
laryngoscopy and for maintanance of anaesthesia. The common side effects seen with 
dexmedetomidine are hypotension and bradycardia. (50,51) 
Gogus et al compared the efficacy of intravenous dexmedetomidine 1µg/kg infusion in 
10 minutes with fentanyl 2µg/kg and with esmolol 2 mg/kg given 2 minutes before 
induction of anaesthesia in decreasing the haemodynamic response to laryngoscopy and 
intubation. Induction of anaesthesia was done with thiopentone 6mg/kg, with vecuronium 
0.1mg/kg providing for muscle relaxation. Tracheal intubation was performed 3 minutes 
after induction. They concluded that dexmedetomidine was superior in decreasing the 
tachycardia following tracheal intubation.(52) 
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Smitha KS et al studied the efficacy of different doses of dexmedetomidine in ablation of 
sympathetic response to endotracheal intubation. They compared between 
dexmedetomidine 0.5µg/kg and 1µg/kg given over 10 minutes before endotracheal 
intubation. Induction of anaesthesia was done with fentanyl 1-2µg/kg and sleep dose of  
propofol, with muscle relaxation provided by vecuronium 0.1mm/kg. It was concluded in 
their study that dexmedetomidine 1µg/kg was more effective in ablation of 
haemodynamic response to intubation than dexmedetomidine 0.5µg/kg.(20) 
Volatile anaesthetics 
MAC intubation is the minimum alveolar concentration of inhalational anaesthetic that is 
necessary to prevent the stress response to endotracheal intubation. Volatile anaesthetics 
in low concentration (0.6-1MAC) may help prevent the increase in blood pressure 
following noxious stimuli. 
Nitroglycerine 
Nitroglycerine is a peripheral vasodilator which acts principally on the veins. It acts by 
generating nitric oxide which is a potent vasodilator. It has a rapid onset of action with 
peak effect in 2-5 minutes. The total duration of action is also very short, about 5 to 10 
minutes. The elimination half life is 1.5 minutes 
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It is used in the treatment of angina pectoris as it reduces the preload, afterload and 
oxygen requirement. It also causes dilatation of coronary blood vessels and redistribution 
of blood flow to ischemic areas. It is also used in the management of acute hypertension, 
for providing controlled hypotension, cardiac failure, and to decrease the stress response 
to laryngoscopy and endotracheal intubation.The commonest side effect is headache. The 
other side effects are postural hypotension, meth-hemoglobulinemia, tachycardia, nausea, 
vomiting, giddiness, intolerance and chest discomfort. (31,53) 
 
 
Fig.12: Structure of Nitroglycerine. 
Safavi et al compared the efficacy of intravenous nitroglycerine 5µg/min given as 
infusion with the same repeat dose every 5 minutes till the systolic blood pressure was 
between 120 to140mmHg, with intravenous hydralazine 5mg initially and further doses 
of 10 mg as per the recommendations of American College of Obstetrics and 
Gynaecology and with sublingual nifidipine 10mg in patients with pre-eclampsia. The 
study drug was administered after 5 minutes of pre-oxygenation. Anaesthesia was 
induced with thiopentone 5mg/kg and tracheal intubation was performed 1 minute after 
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intravenous administration of succinyl choline 1.5mg/kg. It was concluded that 
intravenous nitroglycerine attenuated the haemodynamic effects of intubation better than 
intravenous hydralazine or sublingual nifedipine.(54) 
Sodium nitroprusside 
It is a non selective directly acting peripheral vasodilator. It has an immediate onset and 
short duration of action. It acts via the formation of nitric oxide. It is used for 
hypertensive emergencies, for providing controlled hypotension during anaesthesia and 
surgery, in acute and chronic heart failure, in the surgery for pheochromocytoma, in 
cardiac surgeries that requires bypass, to decrease transfusion need and to decrease the 
stress response to laryngoscopy and intubation with a dose of 1–2 microgram/kg rapid 
I.V  prior to intubation. 
 
 
        Fig.13: Structure of Sodium nitroprusside. 
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Its side effects include bradyarrythmias, tachyarrythmias, hypotension, raised intracranial 
pressure, metabolic acidosis, methhaemoglobulinemia, cyanide poisoning and 
thiocyanate toxicity.(31) 
Labetalol 
 
Fig.14: Structure of Labetalol. 
Labetolol is an alpha and beta receptor antagonist. It acts on alpha 1, beta 1 and beta 2 
receptors. While oral labetalol has a 3:1 beta to alpha blocking potency, it is 7:1 beta to 
alpha receptor blockade for intravenous labetolol. 
Labetalol is used in the management of hypertensive emergencies, angina pectoris and 
for providing hypotensive anaesthesia. Intravenous labetalol 0.1-0.5 mg/kg 5 minutes 
before intubation decreases the stress response to laryngoscopy and intubation. (31) 
Inada et al compared the efficacy of intravenous lignocaine 100mg with labetalol 5mg 
and with labetalol 10mg given 2 minutes before tracheal intubation. They concluded that 
the hypertensive response was similar in all groups, with labetalol 10mg being better in 
controlling tachycardia.(55) 
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Chung et al studied the effects of intravenous labetalol on haemodynamic stress response 
at a dose of 0.4mg/kg given 5 minutes before endotracheal intubation. It was shown that 
the heart rate response to endotracheal intubation was effectively decreased by labetalol, 
but its effect on blood pressure was minimal.(56) 
Calcium channel blockers 
Various calcium channel blockers have been tried in reducing the intubation stress 
response. 
a. Nicardipine  
Mikawa et al compared the efficacy of varying doses of nicardipine 15µg/kg and 30µg/kg 
in attenuating the cardiovascular response to intubation when given 60 seconds prior to 
laryngoscopy. They found that in both groups nicardipine decreased the rise in rate 
pressure product and mean arterial pressure following intubation.(57) 
b. Verapamil 
Yaku et al studied the effects of verapamil on stress response to intubation. The study 
drug was administered at either 0.05mg/kg or 0.1mg/kg and was given 45 seconds prior 
to intubation. It was further compared with a saline group. It was found that the rise in 
mean arterial pressure was significantly lower in patients treated with verapamil although 
it failed to ablate the rise in heart rate following intubation.(58) 
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Mikawa et al compared between the various calcium channel blockers. 60 normotensive 
patients undergoing rapid sequence induction were selected for the study and were 
divided into 4 groups. Each group received either saline, nicardipine 30µg/kg/min, 
verapamil 0.1mg/kg or diltiazem 0.2mg/kg.   While verapamil was given 45 seconds prior 
to intubation, other drugs were administered 60 seconds prior. The rise in arterial 
pressure following intubation was reduced by all calcium channel blockers, with 
verapamil attenuating the heart rate response when compared to other calcium channel 
blockers.(59) 
Newer calcium channel blockers like nilvadipine have also been tried for decreasing the 
stress response to intubation.(60) 
Other drugs 
Other drugs that have been tried for decreasing the stress response to intubation includes 
magnesium sulphate(61), ganglion blockers like trimethaphan(62), adenosine 
triphosphate(63), pindolol(64), diazoxide(65), mexiletine(66) and manidipine(67) to 
name a few. 
In recent times various modalities have been employed to modify the stress response that 
occurs with laryngoscopy and endotracheal intubation. It has been either by the usage of 
premedication, deepening the plane of anaesthesia, use of ganglion blockers, or by the 
use of drugs like sodium nitroprusside, nitrogylecerine , calcium channel blockers , 
intravenous lignocaine to name a few. (68) But these modalities have had their own 
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limitations.  While the use of calcium channel blockers resulted in reflex tachycardia, 
sodium nitroprusside/ nitroglycerine required invasive monitoring, and lignocaine gave 
inconsistent results. Recently, esmolol a short acting beta blocker was found to be 
extremely effective in decreasing the stress response. The efficacy of esmolol bolus in 
decreasing intra-operative tachycardia has been well documented in recent studies. (69) 
Esmolol 
Esmolol is a short acting cardio-selective beta blocker. It can be used as both bolus and 
infusion. In bolus dosing, esmolol at a dosage of 1.5 mg / kg over 30 seconds 3 minutes 
prior to laryngoscopy and endotracheal intubation effectively decreases the stress 
response to intubation.(1) In infusion dosing, continuous infusion of esmolol 50 to 300 
microgram / kg / minute following an initial bolus of 0.5 mg/kg over 30 seconds is also 
effective in decreasing the stress response. (6) 
 
Molecular basis of beta receptor function 
All adrenergic receptors are G protein coupled receptors that link to heterotrimeric G 
proteins. Beta receptor has preference for Gs receptor. The response due to activation of 
beta receptor occurs because of effects mediated by G protein on second messenger 
generation and ion channel activity. 
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Structure of beta receptor 
Adrenergic receptors constitute a family of closely related proteins that are functionally 
and structurally related to G protein coupled receptors. Membrane spanning regions are 
crucially involved in ligand binding. These regions appear to create a ligand binding 
pocket analogous to that formed by the membrane spanning regions of rhodopsin to 
accommodate the covalently attached chronophore, with molecular models placing 
catecholamines either horizontally or perpendicularly.(10) 
 
ESMOLOL 
Esmolol is an ultra short acting second generation cardio-selective beta 1 receptor 
blocker. It has a rapid onset of action. It is devoid of any membrane stabilizing effects 
and has little intrinsic sympathomimetic activity. Esmolol is used mainly when a short 
duration of beta blockade is required or in patients who are critically ill.  It is because in 
critically ill patients, side effects of beta blockers like hypotension, bradycardia or heart 
failure cannot be tolerated. Esmolol is administered only intravenously. The commercial 
preparation is buffered to a Ph of 4.5 – 5.5; this being one of the reasons for pain 
occurring on injection with esmolol.  It is also classified as a class II anti arrhythmic 
drug. 
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Fig.15: Structure of Esmolol hydrochloride. 
 
ABSORPTION, FATE AND EXCRETION 
 
Esmolol is administered slowly as an intravenous injection. It has a half life of 
approximately 8 minutes. The approximate volume of distribution is 2 liters’ per 
kilogram. The most unique feature of the drug is its ester function that is incorporated 
into the phenoxy-propanolamine structure. This allows for rapid degradation of esmolol 
by plasma esterases. Less than 1 % is excreted unchanged in urine.(6) However the 
carboxylic acid metabolite of esmolol is longer acting with a half life of approximately 4 
hours. Prolonged infusion of esmolol results in the accumulation of this metabolite, 
which finally gets excreted in urine. As the potency of this metabolite as a beta receptor 
antagonist is extremely low, it does not cause much adverse effects.  
Less than 1% of the drug is excreted unchanged in urine and 75% of the drug is 
recovered as an inactive acid metabolite. Esmolol is compatible with most of the 
commonly used intravenous solutions and non depolarizing muscle relaxants. Esmolol 
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has poor lipid solubility, which limits its transfer across the placenta and blood brain 
barrier. 
Esmolol has a negative inotropic and chronotropic effect. It decreases the conduction 
speed through the atrio-ventricular node and reduces the rate of spontaneous phase 4 de-
polarization. The most common use of esmolol in surgical patients is either to prevent or 
treat tachycardia. Another common use is in the management of supraventricular 
tachycardia. Esmolol has a rapid onset of action, with peak concentration getting 
achieved in 3 to 10 minutes after giving the loading dose. There is considerable reduction 
of beta antagonism within 20 minutes of stopping the infusion. Normal patients exhibit 
striking hypotension with esmolol. The underlying mechanism for this hypotensive effect 
is not yet clear. 
The drug esmolol is given in emergency settings where rapid beta blockade is required. 
So in the case of esmolol infusion, it is preceded by a loading dose. If the required effect 
is not seen within 5 minutes, the dose is repeated with the same loading dose but with a 
higher infusion rate of the maintenance dose. This can be continued until the desired 
effect is obtained. Esmolol is useful in situations where blood pressure, heart rate and 
cardiac output are elevated. It is also a useful drug to treat severe post operative 
hypertension. The American Heart Association does not recommend the use of esmolol 
in patients having bradycardia, patients who are on other beta blockers and in patients 
with decompensated heart failure as their myocardial function may be compromised. 
(10,31)  
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Dosage – In bolus dosing, esmolol at a dosage of 1.5 mg / kg over 30 seconds 3 minutes 
prior to laryngoscopy and endotracheal intubation effectively decreases the stress 
response.(1) In infusion dosing, continuous infusion of esmolol 50 to 300 µg/kg/minute 
following an initial bolus of 0.5 mg/kg over 30 seconds is also effective in decreasing the 
stress response. (6) 
De Bruijn et al studied the haemodynamic effects of esmolol in chronically beta blocked 
patients undergoing aorto-coronary bypass surgery. They concluded that esmolol did not 
cause any further reduction of heart rate, in response to stress, in patients for whom 
chronic beta blocker therapy was continued till the time of surgery. The addition of 
esmolol however attenuated the increase in blood pressure when compared to the control 
group. (70) 
In a study by Singh et al comparison was made between esmolol 1.4 mg/kg bolus with 
lignocaine 1.5 mg/kg and with nitroglycerine 2 microgram/kg. It was found that esmolol 
was more effective in reducing the the heart rate and mean arterial pressure response 
to intubation when compared to lignocaine. It was found that nitroglycerine, however 
could not effectively decrease the heart rate response to intubation.(71) 
Sampangiramaiah Shailaja et al compared the effects of esmolol bolus 1.5mg/kg with 
esmolol bolus 1.5mg/kg together with fentanyl 2 microgram/kg in decreasing the stress 
response to laryngoscopy and intubation in patients with controlled hypertension. They 
found that esmolol 1.5mg/kg was effective in decreasing the cardiovascular stress 
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response to laryngoscopy and intubation without causing much haemodynamic 
disturbances whereas esmolol 1.5mg/kg together with fentanyl 2 microgram/kg was 
found to cause hypotension following intubation.(68) 
Bakiye Ugur et al conducted a study comparing the effects of esmolol bolus 1.5mg/kg 
with lignocaine 1.5mg/kg and with fentanyl 1 microgram/kg on the haemodynamic stress 
response when given 2 minutes prior to intubation. It was observed that esmolol bolus 
was more effective in decreasing the intubation response. (72) 
In another study conducted by Feng et al, esmolol 2 mg/kg was compared to fentanyl 
3microgram/kg and lignocaine 2mg/kg. The study drug was given 3 minutes prior to 
intubation and they concluded that only esmolol bolus could offer reliable protection 
against tachycardia and rise in systolic blood pressure after laryngoscopy and 
intubation.(73) 
Menigaux et al in his study has shown that esmolol prevents movement and attenuates 
BIS response to orotracheal intubation at a dose of 1mg/kg followed by 250 microgram / 
kg / minute. (74)  
In a study by Wilson et al where esmolol 1mg / kg bolus was given followed by an 
infusion of 250 microgram / kg / minute, it was found that esmolol administered to un-
stimulated anaesthetized patients has a peak effect at 1 to 2 minutes, although in some 
patients it can last up to 5 minutes. (75) 
Like intubation, extubation also causes sympathetic stimulation which manifests as an 
increase in heart rate and blood pressure. Esmolol given at 0.5 mg/kg followed by 150 
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microgram/ kg /minute infusion effectively decreases the extubation response. (76) 
There have been several studies done with Esmolol (either used alone as a bolus or as a 
small loading dose followed by infusion which has been aimed at noting the efficacy of 
this drug in reducing the stress response to laryngoscopy and intubation. One such study 
by Yazicioglu et al in which used a bolus dose of 1mg/kg esmolol 10 minutes before 
endotracheal intubation did not help suppress the haemodynamic stress response. So they 
suggested in their study that in cases where esmolol is given 10 minutes prior to 
intubation, an infusion would be better in reducing the stress response to endotracheal 
intubation. (77) 
Miller DR et al in his study noticed that esmolol bolus when given along with a low dose 
narcotic effectively reduces the systolic blood pressure and heart rate response to 
intubation. (78)  
P Gupta et al compared the effects of nitroglycerine infusion and esmolol infusion in 
decreasing the haemodynamic effects of intubation. They concluded that esmolol 
infusion effectively reduced the heart rate and blood pressure response to intubation   
more than nitroglycerine.  (79)  
Ersa Mercagnoolu Efe et al compared the effects of esmolol bolus with esmolol infusion 
on stress response during laryngoscopy, skin incision and sternotomy in coronary artery 
bypass graft surgery. In the bolus group they used a dosage of 1.5mg/kg and in the 
infusion group a dose of 500 microgram/kg/minute for 10 minutes before intubation 
which was continued for 5 minutes post intubation. They concluded that esmolol infusion 
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was more effective in controlling the systolic blood pressure change and the bolus was 
more effective in controlling the heart rate response to stress. (80)  
 Liu PL et al studied the effects of esmolol infusion in decreasing the stress response to 
intubation in 30 ASA I patients. The study group received an infusion of 
500μg/kg/minute esmolol for 4 minutes followed by 300μg/kg/minute for 8 minutes thus 
adding up to a total duration of 12 minutes. Anaesthesia was induced five minutes after 
the start of esmolol infusion with thiopentone with succinyl choline being used for 
muscle relaxation. They concluded that even though esmolol infusion decreased the 
cardiovascular stress response to intubation, it did not eliminate it completely. (81) 
 
EVOLVING DRUGS FOR ATTENUATING THE STRESS RESPONSE TO 
INTUBATION 
Gabapentin 
Originally used as an anticonvulsant, gabapentin has proved to be effective in controlling 
the stress response to intubation. Montazeri K et al conducted a study comparing the 
efficacy of oral clonidine 0.3mg with oral gabapentin 800mg premedication in decreasing 
the haemodynamic stress response to endotracheal intubation. The study drugs were 
given 90 minutes prior to surgery. Heart rate, systolic arterial pressure, diastolic arterial 
pressure , mean arterial pressure and rate pressure product were measured at baseline (3 
min before induction), just before laryngoscopy, and post intubation (at 1, 3, 5, 10 and 15 
min after starting laryngoscopy).This study demonstrated that premedication with oral 
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gabapentin 800 mg or clonidine 0.3 mg had a similar blunting of the hyperdynamic 
response after laryngoscopy and intubation.(82) 
Memis et al compared two doses of oral gabepentin 400mg and 800mg and their efficacy 
in reduction of stress response to intubation. The study drug was given one hour prior to 
surgery. Changes in heart rate and mean arterial pressure were monitored after intubation. 
They concluded that  oral gabapentin 800mg given one hour prior to surgery was a safe 
and effective method to decrease the stress response to intubation.(83) 
 
Nalbuphine 
Nalbuphine is a synthetic opioid agonist-antagonist. It acts as an agonist at the κ receptor 
and as an antagonist at the µ receptor. It has been tested for decreasing the 
haemodynamic stress response to intubation. Kothari et al compared the efficacy of 
pentazocine with nalbuphine to decrease the stress response to intubation in ASAI and II 
patients. Nalbuphine 0.2mg/kg or pentazocine 0.5mg/kg was given 5 minutes before 
induction of anaesthesia. Thiopentone was the induction agent used and intubation was 
performed after administration of succinyl choline. They concluded in their study that 
nalbuphine effectively reduces hypertension, tachycardia and cardiac workload 
associated with endotracheal intubation.(84) 
 
Landiolol 
Landiolol is a newly developed short acting beta 1 receptor blocker. It has been tried for 
the attenuation of cardiovascular responses to intubation. Goyagi et al used landiolol 
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125µg/kg/min for one minute followed by 40µg/kg/min infusion for four minutes in their 
study. Anesthesia was induced four minutes after starting landiolol, with propofol and 
succinyl choline. They noticed a fall in heart rate and systolic blood pressure in the pre-
intubation period after the administration of landiolol. They concluded in their study that 
continuous administration of landiolol helps in decreasing the stress response to 
intubation.(85) 
 
Pregabalin 
Pregabalin is a calcium channel blocker which decreases the release of glutamine, 
substance P and nor adrenaline. Gupta et al gave oral pregabalin 150mg as premedication 
60-75 minutes before surgery. They noticed that pregabalin significantly decreased the 
hypertensive response to intubation, but the heart rate response to intubation was not 
effectively reduced.(86)   
 
Lornoxicam 
Lornoxicam is a non steroidal anti-inflammatory drug. Daarbiss et al studied the efficacy 
of lornoxicam in decreasing the stress response to intubation. In their study they 
concluded that 16mg of lornoxicam given 30 minutes before surgery effectively reduced 
the pressor response to intubation.(87) 
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 METHODS 
 
STUDY DESIGN 
 
After obtaining the approval of the Institutional Review Board, we conducted a 
randomized controlled trial comparing Esmolol bolus with Esmolol infusion in reducing 
the peri-intubation stress response in non cardiac surgical patients undergoing general 
anaesthesia with endotracheal intubation. 
 
Various drugs have been used to decrease the stress response to intubation. Esmolol is an 
ultra short acting beta 1 blocker which has been proven to be beneficial and more 
effective than many of the commonly used drugs in reducing the intubation response. 
 
Esmolol itself can either be used as an infusion or as a bolus for the purpose of 
decreasing the intubation response. The aim of our study is to find out which mode of 
administration of esmolol reduces intubation response effectively with minimal side 
effects.  
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                                                            FLOW CHART 
                                                                 Study group 
 
                                                         Block randomization 
 
 
 
                                     Group A                                                              Group B 
 
Intervention: Esmolol bolus                              Esmolol loading dose 0.5mg/kg followed  
1.5 mg/kg over 30 seconds                                by infusion (153µg/kg/min) for 6.5 minutes and         
and intubation after 3 minutes                       intubation after two minutes 
 
Change in heart rate, systolic,                           change in heart rate, systolic, diastolic 
diastolic and mean arterial pressure.             and mean arterial pressure. 
Side effects of esmolol                                          Side effects of esmolol 
 
Primary and secondary outcomes                   Primary and secondary outcomes 
 
                 Statistical analysis                                            Statistical analysis                                                            
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STUDY POPULATION 
Inclusion Criteria: 
-Adult patients in the age group of 18-70 years admitted for non cardiac surgery and    
have consented for the study 
Exclusion Criteria: 
-Pregnancy 
-Heart rate less than 60 per minute 
-Systolic blood pressure less than 100mm Hg 
-Hepatic failure 
-Renal failure 
-Cardiac conduction abnormalities 
-Patients on beta blockers 
-History of asthma or chronic obstructive pulmonary disease 
-History of intolerance to beta blockers 
-Obesity (body mass index more than 30) 
-Total duration of laryngoscopy more than 30 seconds 
-Patients who are unable to understand and give consent for participation. 
-Patients less than 18 and more than 70 years old. 
-Patients who are part of other studies. 
-Difficult airway. (appendix 1) 
- ASA PS III and IV. (appendix 2) 
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SAMPLE SIZE CALCULATION 
Sample size for comparing two proportions 
 
P1 –P2 = d 
P1 = effective beta blockade with minimal side effects in esmolol infusion group 
P2 =   = effective beta blockade with minimal side effects in esmolol bolus group. 
P1 =90%     P2 = 70% 
P1 –P2 =d  
ie 90 – 70 = 20 
 _ 
P = (P1 + P2) / 2 = (90 +70) /2 =80 
 
d/ SE =  Zα 
 d / √ (PQ/n1 + PQ/n2 ) =  Zα 
 d / √2 (PQ/n)  = Zα 
 n = ( [2*PQ] / d2 ) *  Zα 2          
 n = ( [2*PQ] / d2 ) * ( Zα + Zβ)2  
 n = (2 * 80*20* (1.96+ 0.84)2 ) / 20 *20 
           = 63 in each arm 
          
      SE = standard error 
        n 1 = number in P1 group 
        n 2 = number in P2 group 
        Zα = type 1 error = 0.05 = 1.96 
        Zβ = type 2 error = 0.2 = 0.84 
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Methodology 
 
An informed consent was obtained from the participants of the study as an initial step. 
The patients were given an oral pre-medication consisting of tablet diazepam 5mg and 
tablet metaclopramide 10mg at approximately 2 hours prior to surgery. Vasoactive drugs 
like atropine, ephedrine and phenylephrine along with all other emergency drugs were 
kept ready inside the theatre. After shifting the patient to the operating table, the first step 
was to obtain a peripheral intravenous access. Then monitors like pulse oximeter, 5 lead 
ECG and non invasive blood pressure monitoring were attached and baseline oxygen 
saturation, heart rate, systolic blood pressure, diastolic blood pressure and mean blood 
pressure were recorded.  
The induction of anaesthesia was similar for both groups in which fentanyl 2mcg/kg, 
propofol 2mg/kg, isoflurane 2% and atracurium 0.5mg/kg was used. Minimum alveolar 
concentration of Isoflurane at the time of intubation was kept between 0.8-0.9 for all 
patients. 
In the esmolol bolus group, a pre calculated dose of esmolol (1.5mg/kg) was given over 
30 seconds following administration of the muscle relaxant. The patient was then 
intubated after a period of 3 minutes.  
In the esmolol infusion group, a loading dose of esmolol 0.5 mg /kg was given over 30 
seconds through a dedicated intravenous line, followed by an infusion of 150mcg/kg/min 
over 6.5 minutes, thereby making it a total of 7 minutes.  The patient was induced 5 
58 
 
minutes after starting the infusion and endotracheal intubation performed 2 minutes after 
stopping the infusion.  
In both groups’ heart rate, systolic, diastolic and mean blood pressures were monitored; 
immediately after attaching the monitors (baseline), every minute prior to intubation for 2 
minutes, and every minute post intubation for 5 minutes. Intubation was performed by an 
anaesthesiologist who had completed a minimum of one year training in our department. 
The intubation time calculated from the time of removal of the face mask to the inflation 
of the endotracheal tube cuff was kept to less than 30 seconds. The intubation time was 
monitored by an assistant on the clock. Anaesthesia was maintained with oxygen, air, 
isoflurane and top ups of muscle relaxant. 
Any significant change, which was taken as a change of ±20 % from the baseline, is 
recorded. A reduction in heart rate to less than 60 per minute or a fall in mean arterial 
pressure to less than 60 mmHg or a 20 % change from the baseline value which was not 
getting corrected within the next 2 minutes warranted an intervention. It was decided to 
wait for 2 minutes before intervening as esmolol is an ultra short acting beta blocker 
whereby the changes in blood pressure and heart rate caused by the drug stabilises 
rapidly.  
A decrease in heart rate was treated with injection atropine (0.3- 0.6mg) and a fall in 
blood pressure was treated with injection ephedrine (5-10mg) or injection 
phenylephrine(50-100µg). An increase in heart rate and blood pressure was treated with 
small bolus doses (0.25-0.5mg/kg) of injection propofol or injection fentanyl (10-
20mcgs). 
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Calculation of dose for infusion: In order to maintain uniformity, the total dose of drug 
given in both groups was kept at 1.5mg/kg. First the total dose of drug was calculated at 
1.5mg/kg body weight of which 0.5 mg/kg was given as bolus over 30 seconds. 
Remaining 1mg/kg was given as infusion over 6.5 minutes so that the total duration of 
drug administration in the infusion group was 7 minutes.  
 
The infusion rate was calculated in the following manner: 
1 mg/kg of esmolol was taken in a 20 cc syringe and diluted to make each ml 5 mg/kg. 
Patient weight / 6.5 gave the dose that needed to be given in mg per minute 
Since each ml was 5 mg, dose to be given in mg per minute divided by 5 gave the dose in 
ml per minute.That value multiplied by 60 gave the rate to be infused in ml per hour. 
The arterial extension was flushed separately with esmolol 5mg/ml to remove the dead 
space and then attached to a 20cc syringe to start the infusion. 
By using the above mentioned calculation, the approximate infusion dose that the patient 
received was 153 microgram / kg / minute after the initial bolus of 0.5 mg/kg. 
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RESULTS AND ANALYSIS 
 
BASELINE VALUES 
 
VARIABLE INFUSION (N=44) BOLUS (N=45) P VALUE 
MALE/FEMALE 28/16 30/5 0.76ᵃ 
AGE  mean (sd) 36.39(11.65) 34.42(12.27) 0.441ᵇ 
BMI mean(sd) 24(3.17) 22.7(3.52) 0.072ᵇ 
BASELINE HR mean(sd) 83.59(14.85) 84.4(13.51) 0.788ᵇ 
BASELINE SBP mean (sd) 133.55(19.41) 129.49(18.78) 0.319ᵇ 
BASELINE DBP mean (sd) 82.64(12.87) 77.56(10.73) 0.046ᵇ 
BASELINE MAP mean 
(sd) 
99.59(14.53) 94.96(12.69) 0.112ᵇ 
Table.1: Comparison of demographic and baseline variables in Esmolol bolus and infusion groups. 
a=chi square, b= t test   
sd= standard deviation. 
BMI = Body mass index 
HR = Heart rate 
SBP = Systolic blood pressure 
DBP = Diastolic blood pressure 
MAP = Mean arterial pressure  
All the baseline variables between the two groups were comparable as the p value is more 
than 0.05. In diastolic blood pressure p value was 0.046 which is approximately equal to 
p=0.05. 
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Fig.16: Pie diagram showing the gender distribution. 
 
The pie diagram shows the percentage of males and females who participated in the 
study. The study had a total number of 58 males and 31 females which corresponded to 
65.2% and 34.8% respectively. While the infusion group had 28 males, the bolus group 
had 30 males. The number of females was 16 and 15 in the infusion and bolus group 
respectively. The p value of 0.76 obtained for gender distribution between the bolus and 
infusion group states that there is no statistically significant difference in the number of 
males and females in both the groups. 
 
 
Gender
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34.8%
65.2%
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Fig.17: Pie diagram showing the distribution of co-morbidities in the study population. 
 
Though the study included all non cardiac surgical patients, the majority of the 
participants were ASA 1 patients. The infusion group had 38 patients without any co-
morbidity whereas the bolus group had 42 patients of the same. 6 patients in the infusion 
group had some associated co-morbidity. Of the 6, two were hypertensives and four were 
diabetics. The bolus group had 3 patients with associated co-morbidities. Of the 3, two 
were hypertensives and one, a diabetic. This has been summarized in the pie- chart 
above. 
89.9
4.5
5.6
Co-morbidities
None
Hypertension
Diabetes
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Overall, while hypertensives constituted 4.5% of the study population, 5.6% were 
diabetics. There was no statistically significant difference in co-morbidities between the 
two groups as the p value obtained was 0.276. 
 
Fig.18: Comparison of the body mass index of the study population in Esmolol bolus group with Esmolol infusion 
group. 
 
 
 
 
This graph shows body mass index along the X axis and number of patients along the Y 
axis. Maximum number of patients in the infusion and bolus group was in the body mass 
index range of 20 to 25 kg/m
2
. There was no statistically significant difference between 
the two groups with regards to body mass index as the p value was 0.072. 
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Fig.19: Comparison of the age of the study population in Esmolol bolus group with Esmolol infusion group. 
 
 
Age 
group 
  
Infusion 
         
Bolus 
≤25     8  11 
26-35    13 18 
36-45    16 7 
≥45     7 9 
 
 
In the above graph, age is shown along the X axis and number of patients along the y 
axis. There was no statistically significant age difference between the two groups as the p 
value was more than 0.05. 
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Fig.20: comparison of pre-intubation haemodynamic changes between Esmolol bolus with Esmolol infusion group. 
 
Pre-intubation Infusion: n (%) Bolus: n (%) P value 
tachycardia 6 (13.64) 6 (13.33) 0.96ᵇ 
bradycardia 0 (0) 6 (13.33) 0.012ᵇ 
hypotension 10 (22.73) 19 (42.22) 0.05ᵇ 
hypertension 0 (0) 1 (2.22) 0.320ᵇ 
none 29 (56.82) 19 (15.56) 0.025
b
 
Table.2: Comparison of pre-intubation haemodynamic variables between Esmolol bolus and infusion groups. 
b= t test; n = number 
6 patients in the bolus group and 6 of the infusion group had pre-intubation tachycardia. 
Pre-intubation hypotension was present in 10 and 19 patients respectively of the infusion 
and bolus group respectively. While none of the patients in the infusion group had pre-
intubation hypertension, one patient in the bolus group had pre-intubation hypertension. 
No other complications were noted in the study group during this period. As the p value 
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for tachycardia, hypotension and hypertension is not less than 0.05, there was no 
statistically significant difference between the two groups.  
While 6 patients in the bolus group had pre-intubation bradycardia, none of the 
participants in the infusion group had pre-intubation bradycardia. The p value for 
bradycardia between the two groups was 0.012 which is statistically significant. 
Haemodynamic instability was absent in 29 patients of the infusion group whereas the 
corresponding figure for those in the bolus group was 19. The p value between the two 
groups was 0.025 and it was found to be statistically significant.  
 
 
Fig.21: Comparison of post-intubation haemodynamic changes between Esmolol bolus and Esmolol infusion group. 
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Post intubation Infusion n (%) Bolus n (%) P value 
tachycardia 19  (43.18) 15 (33.33) 0.339ᵇ 
bradycardia 4 (9.09) 4 (8.89) 0.973ᵇ 
hypotension 24 (54.55) 22 (48.89) 0.593ᵇ 
hypertension 6 (13.64) 5  (11.11) 0.717ᵇ 
none 6 (13.64) 12 (26.67)  0.126
b
 
Table.3: Comparison of post-intubation haemodynamic variables between Esmolol bolus and Esmolol infusion 
groups. 
b= t test, n = number 
 
Following intubation, among the infusion group, 19 patients had tachycardia, 4 had 
bradycardia, 24 had hypotension and 6 patients had hypertension. Correspondingly 
among the bolus group, 15 patients had tachycardia, 4 had bradycardia, 22 had 
hypotension and 5 patients had hypertension. As the p value between the variables of the 
two groups were more than 0.05, the differences were statistically insignificant.  
While 6 patients of the infusion group did not show any post intubation haemodynamic 
instability, the corresponding number for those the bolus group was 12. The p value 
obtained was 0.126; thereby proving the difference between the two groups to be 
statistically insignificant. 
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Fig.22: Comparison of Esmolol bolus and Esmolol infusion with regards to changes in heart rate over a period of 2 
minutes pre-intubation to 5 minutes post-intubation. 
 
 INFUSION MEAN (95%CI) BOLUS MEAN (95%CI) 
Baseline heart rate 83.59 (79.2,87.98) 84.4  (80.45,88.35) 
Pre-intubation heart rate 1 81.55 (77.72,85.37) 81.13  (77.24,85.02) 
Pre-intubation heart rate 2 81.14 (77.4,84.87) 81.73  (78.35,85.11) 
Post-intubation heart rate 1 87.82 (83.86,91.78) 89.62  (86.11,93.14) 
Post-intubation heart rate 2 91.77 (88.36,95.18) 90.29  (87.08,93.5) 
Post-intubation heart rate 3 91.16 (87.74,94.58) 90.69  (86.79,94.59) 
Post-intubation heart rate 4 90.45 (86.77,94.14) 88.56  (84.66,92.45) 
Post-intubation heart rate 5 86.3   (82.59,90) 86.91  (83.44,90.38) 
Table.4: Table comparing mean values of heart rates in Esmolol infusion and bolus groups. 
CI = confidence interval 
As the time changes there is a significant difference in heart rate (p <0.001), but the 
difference between two arms is not clinically significant. (p=0.86). 
    
 
75
80
85
90
95
100
M
ea
n
Infusion Bolus
hr = Heart rate 
pre = preintubation 
post = postintubation 
1- first minute 
2- second minute 
3- third minute 
4- fourth minute 
5- fifth minute 
69 
 
 
 
Time P value 
Pre-intubation 1
st
 minute 0.268 
Pre-intubation 2
nd
 minute 0.184 
Post-intubation 1
st
 minute 0.022 
Post-intubation 2
nd
 minute <0.001 
Post-intubation 3
rd
 minute <0.001 
Post-intubation 4
th
 minute <0.001 
Post-intubation 5
th
 minute 0.143 
 Table.5: Statistical significance of the changes in heart rate from the base line value per unit time in the esmolol 
infusion group. 
In the infusion group, there is a fall in heart rate in the pre-intubation period as evidenced 
from the graph. But the fall from the baseline value is not statistically significant as the p 
value for the difference in heart rate between the baseline and the first and second minute 
pre-intubation is more than 0.05.Immediately after intubation there is a rise in heart rate 
from the baseline which stabilizes in the fifth minute. The post-intubation rise in heart 
rate from the baseline for the first four minutes is statistically significant as the p value is 
less than 0.05. Thus, we infer that esmolol infusion failed to protect effectively against 
post-intubation tachycardia in this study. 
Time P value 
Pre-intubation 1
st
 minute 0.074 
Pre-intubation 2
nd
 minute 0.144 
Post-intubation 1
st
 minute 0.004 
Post-intubation 2
nd
 minute 0.001 
Post-intubation 3
rd
 minute 0.001 
Post-intubation 4
th 
minute 0.023 
Post-intubation 5
th 
minute 0.169 
Table.6: Statistical significance of changes in heart rate from the base line value per unit time in the esmolol bolus 
group. 
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In the bolus group, there is a decrease in heart rate in the pre-intubation period with the 
bolus dose of esmolol. But the fall in heart rate from the baseline value was not 
statistically significant as the p value for the first and second pre-intubation minutes were 
more than 0.05. Immediately after intubation there is a rise in heart rate from the baseline 
which is getting stabilized in the fifth minute. The post-intubation rise in heart rate for the 
first four minutes was statistically significant as the p value was less than 0.05. Thus, 
bolus dose of esmolol also failed to effectively protect against post-intubation 
tachycardia. 
 
 
   
 
 
Fig.23:  Comparison of Esmolol bolus and infusion with regards to changes in systolic blood pressure over a period 
of 2 minutes pre-intubation to 5 minutes post-intubation. 
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 INFUSION MEAN (95% CI) BOLUS MEAN (95% CI) 
Baseline SBP 133.55(127.81,139.28) 129.49(124,134.98) 
Pre-intubation SBP 1 118.34(111.51,125.17) 109.44(103.68,115.21) 
Pre-intubation SBP 2 117.11(110.62,123.61) 104.96(98.91,111.01) 
Post-intubation SBP 1 119.3(112.79,125.8) 119.53(113.19,125.88) 
Post-intubation SBP 2 120.55(113.66,127.43) 121.2(115.92,126.48) 
Post-intubation SBP 3 117.41(111.03,123.79) 116.58(111.7,121.45) 
Post-intubation SBP 4 116.57(110.46,122.67) 112.84(107.69,118) 
Post-intubation SBP 5 111.8(106.02,117.57) 108.24(103.49,113) 
Table.7: Table comparing mean values of systolic blood pressure in Esmolol infusion and bolus groups. 
CI = confidence interval,   SBP = systolic blood pressure 
As the time changes there is a significant difference in systolic blood pressure (p<0.001). 
The difference between the two arms is also showing significance as the p value is less 
than 0.05 (p= 0.0383). But this difference could be due to the pre-intubation differences 
in the systolic blood pressure between the two arms. The difference is getting stabilized 
in the post-intubation period. 
Time  P value 
Pre-intubation 1
st
 minute <0.001 
Pre-intubation 2
nd
 minute <0.001 
Post-intubation 1
st
 minute <0.001 
Post-intubation 2
nd
 minute <0.001 
Post-intubation 3
rd
 minute <0.001 
Post-intubation 4
th 
minute <0.001 
Post-intubation 5
th
 minute <0.001 
Table.8: Statistical significance of the changes in systolic blood pressure from the base line value per unit time in the 
esmolol infusion group. 
There is statistically significant decrease in the systolic blood pressure in the pre-
intubation and post-intubation period in the esmolol infusion group (p value < 0.05). 
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Time  P value 
Pre-intubation 1
st
 minute <0.001 
Pre-intubation 2
nd
 minute <0.001 
Post-intubation 1
st
 minute 0.001 
Post-intubation 2
nd
 minute 0.007 
Post-intubation 3
rd
 minute <0.001 
Post-intubation 4
th
 minute <0.001 
Post-intubation 5
th 
minute <0.001 
Table.9: Statistical significance of the changes in systolic blood pressure from the base line value per unit time in the 
esmolol bolus group. 
There is a statistically significant fall in systolic blood pressure in the pre-intubation and 
post-intubation period when compared to the baseline (p value < 0.05). 
 
 
Fig.24: Comparison of Esmolol bolus and infusion with regards to changes in diastolic blood pressure over a period 
of 2 minutes pre-intubation to 5 minutes post-intubation. 
 
 
60
65
70
75
80
85
90
M
ea
n
Infusion Bolus
 
 dbp = diastolic blood 
pressure 
pre = pre-intubation 
post = post-intubation 
1- first minute 
2- second minute 
3- third minute 
4- fourth minute 
5-   fifth minute 
 
73 
 
 
 INFUSION MEAN(95% CI) BOLUS MEAN (95%CI) 
Baseline DBP 82.64(78.83,86.44) 77.56(74.42,80.69) 
Pre-intubation DBP 1 75(70.63,79.37) 67.38(63.28,71.47) 
Pre-intubation DBP 2 73.73(68.94,78.51) 65.31(61.39,69.24) 
Post-intubation DBP 1 77.7(73.11,82.3) 74.4(69.64,79.16) 
Post-intubation DBP 2 76.95(71.72,82.18) 76(71.76,80.24) 
Post-intubation DBP 3 74.82(69.92,79.72) 72(68.59,75.41) 
Post-intubation DBP 4 72.43(67.96,76.9) 67.89(64.46,71.32) 
Post-intubation DBP 5 68.98(64.92,73.04) 64(61.07,66.93) 
Table.10: Table comparing mean values of diastolic blood pressure in Esmolol infusion and bolus groups. 
CI = confidence interval; DBP = Diastolic blood pressure                   
                          
There is a significant difference in the change of diastolic blood pressure within the two 
arms from the baseline to the 5
th
 minute post intubation (p=0.0001). But there is no 
statistically significant difference between the two arms (p = 0.3676). 
 
Time  P value 
Pre-intubation 1
st
 minute   0.001 
Pre-intubation 2
nd
 minute <0.001 
Post-intubation 1
st
 minute   0.037 
Post-intubation 2
nd
 minute   0.016 
Post-intubation 3
rd
 minute   0.001 
Post-intubation 4
th
 <0.001 
Post-intubation 5
th
 <0.001 
Table.11: Statistical significance of the changes in diastolic blood pressure from the base line value per unit time in 
the esmolol infusion group. 
 
Diastolic blood pressure showed a significant fall in the pre-intubation and post-
intubation period in the esmolol infusion group. 
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Time  P value 
Pre-intubation 1
st
 minute <0.001 
Pre-intubation 2
nd
 minute <0.001 
Post-intubation 1st minute   0.177 
Post-intubation 2
nd
 minute   0.506 
Post-intubation 3
rd
 minute   0.018 
Post-intubation 4
th
minute <0.000 
Post-intubation 5
th
minute <0.000 
Table.12: Statistical significance of the changes in diastolic blood pressure from the base line value per unit time in 
the esmolol bolus group. 
In the bolus group, there is a significant fall in the diastolic blood pressure in the pre-
intubation period from the baseline (p value< 0.05). The changes when compared to the 
baseline value in the first 3 minutes post-intubation are not statistically significant. After 
the third post-intubation minute, the diastolic blood pressure again falls significantly (p 
value< 0.05). 
 
 
Fig.25: Comparison of Esmolol bolus and infusion with regards to change in mean arterial pressure over a period of 
2 minutes pre-intubation to 5 minutes post-intubation. 
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 INFUSION MEAN (95% CI) BOLUS (95% CI) 
Baseline MAP 99.59(95.3,103.88) 94.96(91.25,98.66) 
Pre-intubation MAP 1 89.43(84.46,94.41) 81.29(76.73,85.84) 
Pre-intubation MAP 2 88.09(82.93,93.25) 78.29(73.78,82.79) 
Post-intubation MAP 1 91.57(86.46,96.68) 89.38(84.24,94.52) 
Post-intubation MAP 2 91.5(85.84,97.16) 91(86.62,95.38) 
Post-intubation MAP 3 88.77(83.47,94.08) 86.87(83.13,90.6) 
Post-intubation MAP 4 87.09(82.23,91.95) 82.73(78.92,86.54) 
Post-intubation MAP 5 83.16(78.67,87.65) 78.64(75.23,82.06) 
  Table.13: Table comparing mean values of mean arterial pressure in Esmolol infusion and bolus groups. 
 CI = confidence interval; MAP = mean arterial blood pressure 
           
As the time change there is a significant decrease in the mean arterial pressure within the 
two arms (p < 0.001). However, the change in mean arterial pressure does not show any 
statistically significant difference between the two arm (p=0.1334)   
 
Time  P value 
Pre-intubation 1
st
 minute  <0.001 
Pre-intubation 2
nd
 minute <0.001 
Post-intubation 1
st
 minute   0.001 
Post-intubation 2
nd
 minute   0.001 
Post-intubation 3
rd
 minute  <0.001 
Post-intubation 4
th
 minute <0.001 
Post-intubation 5
th
 minute <0.001 
Table.14: Statistical significance of the changes in mean arterial blood pressure from the base line value per unit 
time in the esmolol infusion group. 
 
In the infusion group there is a significant fall in mean arterial pressure in the pre-
intubation period from the baseline (p value< 0.05). It stabilizes in the initial two minutes 
post intubation, but after that there is a significant fall in mean arterial pressure (p value< 
0.05) 
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Time  P value 
Pre-intubation 1
st
 minute <0.001 
Pre-intubation 2
nd
 minute <0.001 
Post-intubation 1
st
 minute    0.025 
Post-intubation 2
nd
 minute    0.111 
Post-intubation 3
rd
 minute    0.001 
Post-intubation 4
th
 minute <0.001 
Post-intubation 5
th
 minute <0.001 
Table.15: Statistical significance of the changes in mean arterial blood pressure from the base line value per unit 
time in the esmolol bolus group. 
 In the bolus group, there is a significant fall in mean arterial pressure in the pre-
intubation period from the baseline (p value< 0.05). It stabilizes in the initial two minutes 
after intubation, but after that there is a significant fall in mean arterial pressure (p value< 
0.05) 
 
STATISTICAL METHODS 
The data was summarized using mean along with standard deviation for continuous 
variables, and frequency along with percentage for categorical variables. Repeated 
measure ANOVA was used to compare the time change between the two intervention 
arms. Independent t- test and Chi-square test was used to analyze the baseline difference 
among the intervention arms depending on the variable nature (continuous/categorical). 
The significance for all tests was performed at 5% levels. All statistical analysis were 
performed using STATA I/C 13.1 software. A p value of less than 0.05 was taken as 
significant. 
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DISCUSSION 
This randomized controlled study was designed to find out the haemodynamic effects of 
the different modes of administration of esmolol on stress response to laryngoscopy and 
endotracheal intubation. As there are very few studies comparing the effects of esmolol 
bolus with esmolol infusion, we decided to compare the two different modes of esmolol 
administration and its effect on decreasing the stress response to laryngoscopy and 
intubation. 
In our study, with regards to changes in systolic pressure, it was found that there existed a 
significant difference between the two groups. This difference was due to the fact that the 
pre-intubation fall in systolic blood pressure was more with the esmolol bolus group 
when compared to the infusion group. But these changes were seen to stabilize in the post 
intubation period. It was concluded in the study by Ersa Mercagnoolu Efe et al that there 
is no significant difference between esmolol bolus and infusion in decreasing the stress 
response.(80) The same result was obtained in our study except for the pre-intubation 
difference in systolic blood pressure. 
Shailaja S et al compared the effects of esmolol bolus 1.5mg/kg with esmolol bolus 
1.5mg/kg along with fentanyl 2 microgram/kg in decreasing the stress response to 
laryngoscopy and intubation in patients with controlled hypertension. They found that 
esmolol 1.5mg/kg was effective in decreasing the stress response to laryngoscopy and 
intubation without causing much haemodynamic disturbances, whereas esmolol 1.5mg/kg 
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together with fentanyl 2 microgram/kg was found to cause hypotension in the post 
intubation period. (68) We used esmolol along with low dose fentanyl 2µg/ kg in our 
study. The changes in heart rate and blood pressure were consistent with the study by 
Shailaja et al. There was a significant rise in heart rate following intubation which 
reached its maximum in the first post-intubation minute. We also noticed a significant fall 
in blood pressure with the use of esmolol bolus and infusion.  
Reddy et al compared dexmedetomidine 1µg/kg over 10 minutes with esmolol bolus 
2mg/kg given 3 minutes before the induction of anaesthesia in ASA I and II patients. 
Injection thiopentone 5mg/kg was used for induction of anaesthesia and endotracheal 
intubation was performed 1 minute after administration of succinyl choline 2mg/kg. They 
found an increase in mean arterial pressure, systolic blood pressure and diastolic blood 
pressure immediately following intubation.(88) In our study we used a smaller dose of 
esmolol bolus 1.5mg/kg with propofol as the induction agent. In terms of changes in heart 
rate, our study correlated with that of Reddy et al as there is an increase in heart rate 
following intubation. We noticed a significant fall in blood pressure following intubation 
which was more evident with the systolic blood pressure. This difference in our study 
may be due to the difference in the use of induction agent.  
Our study showed a significant rise of heart rate in the post-intubation period in both 
esmolol bolus and esmolol infusion groups. There was no rise in blood pressure 
following intubation; instead there was a significant fall in systolic, diastolic and mean 
arterial pressure. Singh et al compared the effects of low dose esmolol 0.5mg/kg and 
labetolol 0.25 mg/kg in decreasing the stress response to intubation in ASA I and II 
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patients. They found that the hypertensive response to laryngoscopy and endotracheal 
intubation was not effectively reduced by low dose esmolol. But there was  no associated 
side effects like bradycardia or hypotension.(89) In our study with administration of 
esmolol 1.5 mg/kg bolus, 19 out of 45 patients had hypotension in the pre-intubation 
period and 22 out of 45 patients had hypotension in the post-intubation period.  
Singhal et al compared administration of esmolol 1.5 mg/kg at different time intervals to 
decrease the haemodynamic response to intubation. They concluded that esmolol bolus 
1.5 mg/kg given 3 minutes prior to intubation was better than administering the drug 90 
seconds or 6 minutes before laryngoscopy for attenuating the stress response. They also 
noticed a fall in systolic blood pressure after esmolol administration in the pre-intubation 
period. In our study the 1.5 mg/kg bolus dose of esmolol was administered 3 minutes 
prior to intubation. There was a significant fall in systolic blood pressure in the pre-
intubation period after esmolol bolus administration which was consistent with the study 
done by Singhal et al.(90) 
Miller DR et al compared the effects of esmolol 100mg with esmolol 200mg given as a 
bolus over 15 seconds immediately before the induction of anaesthesia. Tracheal 
intubation was performed one minute after administration of the muscle relaxant, 
succinyl choline. It was noticed that esmolol 100mg and 200mg caused a significant 
reduction in the post intubation increase of heart rate and systolic blood pressure although 
it was not completely abolished. The administration of esmolol was associated with a pre-
intubation reduction in systolic blood pressure and the magnitude of reduction was higher 
as the dose of esmolol increases. The administration of esmolol along with fentanyl 
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2µg/kg was associated with better haemodynamic stability after intubation in terms of 
rise in heart rate and systolic blood pressure. They concluded that the administration of 
esmolol 100mg along with low dose narcotic fentanyl 2-3µg/kg provides better 
haemodynamic stability following endotracheal intubation with minimal side effects.(78) 
We used esmolol bolus 1.5mg/kg along with fentanyl 2µg/kg in our study. We noticed a 
pre-intubation significant reduction in systolic blood pressure in the esmolol bolus group. 
There was an increase in heart rate in the first minute which gradually stabilized over 5 
minutes. The post-intubation rise in systolic blood pressure was attenuated by 
pretreatment with esmolol in combination with low dose fentanyl. Even though the rise in 
heart rate was not controlled by esmolol, there was no rise in blood pressure. These 
results of our study are consistent with the study done by Miller DR et al. 
Feng et al in his study with esmolol 2mg/kg in ASA I and II patients noticed that esmolol 
could effectively decrease the rise in heart rate and systolic blood pressure following 
intubation. (73) In our study, though esmolol in both infusion and bolus forms prevented 
any post-intubation increase in systolic blood pressure, but failed to prevent the rise in 
heart rate following intubation. We used a lower dose of esmolol when compared to Feng 
et al. 
Liu PL et al in his study using esmolol infusion for 12 minutes suggested that esmolol 
infusion according to his study settings decreased the cardiovascular responses though 
did not eliminate it completely. (81) We used esmolol infusion with a different dose and 
the duration of infusion was less, but the result obtained suggests that the cardiovascular 
responses are not completely suppressed by the esmolol infusion. 
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Rajbhandari et al studied the effects of esmolol 50mg given intravenously 3 minutes prior 
to laryngoscopy and its influence on the haemodynamic stress response to endotracheal 
intubation. He noticed that 50mg esmolol was ineffective in blunting the stress response. 
Patients had increase in heart rate and blood pressure after intubation.(91) We used a 
higher dose of esmolol bolus which failed to attenuate the heart rate response to 
intubation, but prevented any hypertensive response following infusion. 
The study by Parnass et al comparing between a single bolus dose of esmolol 100mg and 
200mg on the haemodynamic effects of endotracheal intubation when given 2.5-3 
minutes prior to laryngoscopy showed that both 100mg and 200mg esmolol is effective in 
blunting the increase in heart rate and blood pressure following intubation.(92) In our 
study both the bolus dose and infusion of esmolol failed to prevent the post-intubation 
rise in heart rate. 
Kindler et al compared the effects of esmolol 1mg/kg and esmolol 2mg/kg with and 
without lignocaine 1.5mg/kg on ablation of haemodynamic stress response to intubation. 
The study result showed that esmolol alone could reliably decrease the heart rate 
response but only a combination of esmolol and lignocaine decreased both the heart rate 
and blood pressure to intubation. (93) In our study, esmolol in both bolus and infusion 
forms failed to blunt the immediate increase in heart rate following intubation. There was 
significant reduction in blood pressure following administration of esmolol.  
Ebert et al studied the efficacy of esmolol 100mg and 200mg to decrease the 
haemodynamic stress response to intubation given prior to induction in rapid sequence 
induction in ASA I and ASA II patients. They found that both the doses of esmolol 
82 
 
decreased the heart rate and systolic blood pressure response to intubation. They also 
noted a significant reduction in the systolic blood pressure in the pre-intubation 
period.(94) The findings are similar to those in our study except for the fact that esmolol 
did not decrease heart rate response to intubation. There was significant reduction in 
systolic blood pressure in the pre-intubation period. There was no rise in blood pressure 
following intubation. In our study there was a significant fall in blood pressure post-
intubation in both the groups. 
Sharma et al compared the efficacy of esmolol 100mg and 200mg in decreasing stress 
response to intubation in hypertensive patients and concluded that esmolol 100mg is 
better in terms of sustained decrease in blood pressure with esmolol 200mg, which would 
be hazardous to patients.(18) Our study had only 4 controlled hypertensives. On an 
individual basis esmolol bolus did not ablate the heart rate response to intubation while 
post-intubation blood pressure was near the base line. In the infusion group, all the 3 
patients showed significant decrease in mean blood pressure. But the number of 
hypertensives in our study is insufficient to make a comment on the effect of esmolol on 
controlled hypertensives. 
There were 5 diabetic patients in the study. The number is insufficient to make a 
conclusion about the response to esmolol. On an individual basis one patient had post- 
intubation tachycardia and one patient had pre-intubation hypotension. 
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LIMITATION 
1. Although the calculated sample size was 126 patients, the study was stopped at 92 
patients in order to meet the dead line for submission of thesis.  
2. Among the 92 patients 3 patients were excluded from the study after obtaining consent 
because their baseline heart rate showed less than 60 on the day of surgery which comes 
under the exclusion criteria. 
3. We have used non invasive blood pressure monitoring for the study. Usage of invasive 
arterial blood pressure monitoring would have given a more accurate beat to beat blood 
pressure reading. 
4. Although the laryngoscopic duration was kept to less than 30 seconds, no comparison 
was made between the duration of laryngoscopy and the stress response. 
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CONCLUSION 
We found in our study that both esmolol bolus and esmolol infusion reduced the 
hypertensive response to intubation, but the heart rate response to intubation was not 
effectively reduced. 
There was no significant bradycardia in the pre-intubation or post-intubation period. Both 
esmolol bolus and esmolol infusion was associated with significant pre-intubation and 
post-intubation hypotension. Significant pre-intubation tachycardia was not seen in both 
groups. No other side effects of esmolol were noted in the study population.  
We found that there is no statistically significant difference between esmolol bolus and 
infusion in terms of reduction in heart rate, diastolic pressure and mean arterial blood 
pressure. However there was a significant difference in the fall of systolic blood pressure 
over a period of 2 minutes pre-intubation to 5 minutes post-intubation. This difference 
was due to esmolol bolus causing a larger drop in systolic blood pressure during the pre- 
intubation period. 
Based on the study results, we conclude there is no significant difference between 
esmolol bolus and esmolol infusion in the reduction of peri-intubation stress response. 
However, esmolol infusion provided better haemodynamic stability than esmolol bolus. 
Caution should be exercised while giving esmolol bolus at 1.5 mg /kg in patients with 
autonomic dysfunction, myocardial depression and uncontrolled hypertension especially 
when given along with drugs like propofol and inhalational agents. In the predisposed 
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individuals, the above mentioned drugs in combination with esmolol bolus can cause a 
sudden drop in systolic blood pressure after administration. 
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                                                   APPENDICES 
 
APPENDIX 1 
 
 
Difficult airways were excluded from the study which are Mallampati classification more than II, 
short neck, obese patients, external facial and internal airway anomalies causing difficult 
intubation, restricted neck movements, mouth opening less than 2 fingers, buck teeth and 
edentulous. 
 
Mallampatti Classification 
Class I – Visualization of the soft palate, fauces, uvula, anterior and posterior pillars. 
Class II - Visualization of the soft palate, fauces, uvula. 
Class III - Visualization of the soft palate and base of uvula. 
In Samsoon and Young’s modification (1987) of the Mallampati classification a IV class was 
added. 
Class IV – Only hard palate visible. 
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APPENDIX 2 
 
American Society of Anaesthesiologists Physical Status Classification 
 
 
1. Normal healthy individual 
2. Mild to moderate systemic disease not limiting function. 
3. Severe systemic disease, some limitation of function. 
4. Incapacitating systemic disease, constant threat to life. 
5. Not expected to survive more than 24 hours with or without operation. 
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APPENDIX 3 
 
Variable 
Infusion 
n=44 
mean(sd) 
Bolus 
n = 45 
mean(SD) 
age 36.39(11.65) 34.42(12.27) 
bmi 24(3.17) 22.7(3.52) 
baseline_hr 83.59(14.85) 84.4(13.51) 
pre_hr1 81.55(12.94) 81.13(13.31) 
pre_hr2 81.14(12.63) 81.73(11.57) 
post_hr1 87.82(13.41) 89.62(12.03) 
post_hr2 91.77(11.53) 90.29(10.97) 
post_hr3 91.16(11.59) 90.69(13.36) 
post_hr4 90.45(12.49) 88.56(13.33) 
post_hr5 86.3(12.54) 86.91(11.88) 
baseline_sbp 133.55(19.41) 129.49(18.78) 
baseline_dbp 82.64(12.87) 77.56(10.73) 
pre_sbp1 118.34(23.11) 109.44(19.74) 
pre_dbp1 75(14.8) 67.38(14.01) 
pre_sbp2 117.11(21.99) 104.96(20.71) 
pre_dbp2 73.73(16.2) 65.31(13.43) 
post_sbp1 119.3(22.02) 119.53(21.71) 
post_dbp1 77.7(15.56) 74.4(16.3) 
post_sbp2 120.55(23.3) 121.2(18.08) 
post_dbp2 76.95(17.7) 76(14.52) 
post_sbp3 117.41(21.6) 116.58(16.69) 
post_dbp3 74.82(16.58) 72(11.66) 
post_sbp4 116.57(20.66) 112.84(17.64) 
post_dbp4 72.43(15.12) 67.89(11.75) 
post_sbp5 111.8(19.56) 108.24(16.28) 
post_dbp5 68.98(13.74) 64(10.02) 
baseline_map 99.59(14.53) 94.96(12.69) 
pre_map1 89.43(16.84) 81.29(15.59) 
pre_map2 88.09(17.45) 78.29(15.42) 
post_map1 91.57(17.3) 89.38(17.59) 
post_map2 91.5(19.14) 91(14.98) 
post_map3 88.77(17.96) 86.87(12.78) 
post_map4 87.09(16.44) 82.73(13.04) 
post_map5 83.16(15.18) 78.64(11.67) 
Comparison of age,BMI, pre-intubation and post-intubation haemodynamic variables in Esmolol bolus and infusion 
groups. 
BMI = Body mass index 
HR = Heart rate 
SBP = Systolic blood pressure 
DBP = Diastolic blood 
pressure 
MAP = Mean arterial pressure 
PRE    = pre-intubation 
POST = post-intubation 
1- first minute 
2- second minute 
3- third minute 
4- fourth minute 
5- fifth minute 
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INFORMATION SHEET FOR PARTICIPANT. 
 
 
Dear Sir/ Madam, 
 
You are invited to be a part of the study which aims to improve the current knowledge about a 
drug,Esmolol, thatblunts the increase in heart rate and blood pressure following insertion of 
endotracheal tube. The information in this document is meant to help you to decide whether or not 
to take part in this study. This study is being conducted in the department of Anaesthesiology, 
Christian medical college, Vellore. Please read the instructions carefully before signing the 
informed consent documented for participation in this study. Please feel free to ask in case of any 
queries or concerns.  
 
In this study we are comparing two methods of administration of the drug Esmolol which is used 
to blunt the increase in heart rate and blood pressure following insertion of endotracheal tube. The 
methods that are being compared are: administration of the total dose of the drug over 30 seconds 
and administration over a period of 7 minutes. 
 
Esmolol is a short acting drug which is already proven to blunt the unwanted responses following 
insertion of endotracheal tube. Both methods of administration have been proven useful and are 
widely accepted. We are doing this study to find out which method is better to blunt the unwanted 
responses following tube insertion. The expected side effects of the drug area decrease in heart 
rate and blood pressure which can be about 20% from your starting values. But as the drug is 
extremely short acting these effects do not last long and is easily treatable. 
 
By agreeing to participate in this study you will be helping us find the best method of drug 
administration that blunts the increase in heart rate and blood pressure following insertion of an 
endotracheal tube. This study is important because these responses, although well tolerated by a 
healthy individual, can be hazardous in people with hypertension, thyroid disorders, history of 
myocardial ischemia to name a few. 
 
The data obtained will be stored without compromising your identity and confidentiality. By 
signing the document, you will be allowing the research team investigators, other study personnel, 
institutional ethics committee and any person or agency required by law to view your data if 
required. 
 
Your participation in this study is purely voluntary. If you decide not to participate in this study, it 
will in noway affect your medical care or your relationship with the treating doctor, the 
investigator or the institution. The participation in this study is purely voluntary and you have the 
right to withdraw from this study at any time without giving any reasons. 
 
  Thanking you for your co operation, 
 
  Dr. Ann Sumin Toms, 
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  Principal investigator. 
 
Contact persons for any queries. 
 
1. Dr Ann Sumin Toms, 
    Principal investigator, 
  Department of Anaesthesiology, 
  Christian medical college, Vellore. 
   Phone no: 0416 2282105. 
     Mobile no : 8098018088. 
 
2. Dr. Sathish Kumar, 
     Guide and Co investigator, 
     Department of Anesthesiology, 
  Christian medical college, Vellore. 
    Phone no: 0416 2282105. 
    Mobile no:9894682487. 
 
3.Dr.Raj Sahajanandan 
Co Guide, 
Christian Medical College ,Vellore. 
Phone no: 0416 2282105 
Mobile number -8489622336 
Email rajsahajanandan@gmail.com 
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Format for Informed Consent Form for Subjects 
 
Informed Consent form to participate in a research study  
 
Study Title: Comparison between esmolol bolus and esmolol bolus with infusion in 
reducing stress response following intubation in non cardiac surgical patients  
 
Study Number: ____________ 
 
Subject’s Initials: __________________ Subject’s Name: 
_________________________________________ 
 
Date of Birth / Age: ___________________________ 
 
(Subject) 
 
(i)  I confirm that I have read and understood the information sheet dated ____________ for 
the above study and have had the opportunity to ask questions.  
 
(ii)  I understand that my participation in the study is voluntary and that I amfree to withdraw 
at any time, without giving any reason, without my medical care or legal rights being 
affected.  
 
(iii)  I understand that the Sponsor of the clinical trial, others working on the Sponsor’s behalf, 
the Ethics Committee and the regulatory authorities will not need my permission to look 
at my health records both in respect of the current study and any further research that may 
be conducted in relation to it, even if I withdraw from the trial. I agree to this access. 
However, I understand that my identity will not be revealed in any information released 
to third parties or published.  
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(iv)  I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s). 
 
(v)  I agree to take part in the above study.  
 
Signature (or Thumb impression) of the Subject/Legally Acceptable  
 
Date: _____/_____/______ 
 
Signatory’s Name: _________________________________Signature:  
 
Or 
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Representative: _________________ 
 
Date: _____/_____/______ 
 
Signatory’s Name: _________________________________ 
 
 
Signature of the Investigator: ________________________ 
 
Date: _____/_____/______ 
 
Study Investigator’s Name: _________________________ 
 
 
Signature of the Witness: ___________________________ 
 
Date: _____/_____/_______ 
 
Name & Address of the Witness: ______________________________ 
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                                                       PROFORMA 
Comparison of Esmolol bolus against infusion to reduce peri-intubation stress  
response in non cardiac surgical patients 
 
A.  Infusion -1 /bolus – 2.                                       Serial number:            Date: 
 
B.   Name :                                                 Age:          Sex:  male -1,female -2      BMI: 
      Hospital number: 
 
     Associated co morbidity: 
 
C.   Vital Parameters 
 
 HEART 
RATE 
SYSTOLIC BP DIASTOLIC 
BP 
MEAN BP 
BASE LINE     
PREINTUBATION     
1
ST
 MINUTE     
2
ND
 MINUTE     
POST 
INTUBATION 
    
1
ST
 MINUTE     
2
ND
 MINUTE     
3
RD
 MINUTE     
4
TH
 MINUTE     
5
TH
 MINUTE     
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D. Complications                            Pre intubation                     Postintubation 
 
a.  Significantbradycardia                 1-yes, 0- no                             1-yes, 0-no. 
 
     Management:                                    Atropine – 1, other drugs -2 
 
 b. Significant hypotension:              1-yes, 0- no                                  1- yes, 0-no 
 
       Management:      Ephedrine -1, Phenylephrine -2 , others -3 
 
c.  Significant tachycardia                  1-yes,0-no                                    1-yes,0-no 
 
       Management -  fentanyl -1, Propofol -2, others -3. 
 
  d. Significant hypertension                1-yes, 0- no                                   1-yes, 0-no 
 
       Management -  fentanyl -1, Propofol -2, others -3. 
 
  e. Other complications. 
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             DATA SHEET 
 
 
SERIAL NO DATE NAME AGE IN YEARSSEX: M=1; F=2BMI HOSP. NO. CO-MORBIDITY: 0=NONE; 1= HYPERTENSION; 2= DIABETES; 3= OTHERSINFUSION=1; BOLUS=2
1 20.05.2014SUNITA BAURI 33 2 24.9 856769F 0 2
2 21.05.2014BANDARU REDDY 39 1 22.4 907626F 1 1
3 22.05.2014SHANTI KUNDU 46 2 23.3 860618F 0 2
4 6.06.2014 CHANDRASEKHAR N35 1 26.1 907693F 0 1
5 11.06.2014LOBSANG DORJEE 22 1 20.2 766659F 0 1
6 11.06.2014VENKATESAN 35 1 15.8 094549F 0 2
7 13.06.2014SUKUMAR MONDAL55 1 22.9 786559F 0 2
8 18.06.2014SURAJIT KUMAR GUPTA41 1 21.6 846088F 0 1
9 17.06.2014BRISHNA GHOSH 33 2 19.1 822504F 0 2
10 25.06.2014GAUTHAM SAHA 40 1 28.1 876622F 0 1
11 26.06.2014HARJAN KAUR 62 2 18.8 817648F 0 2
12 01.08.2014BEENA DEVI 37 2 21.5 857905F 0 1
13 01.08.2014BANDANA GHOSH 44 2 19.2 011070G 0 1
14 04.08.2014DEEPAK KUMAR 28 1 21.3 828424F 0 1
15 05.08.2014SUMATI DUTTA 39 2 19.8 875583F 0 2
16 06.08.2014SASHIKANT TIWARI 22 1 23.7 827579F 0 2
17 06.08.2014JULFUKAR SAHA 40 1 22.7 886623F 0 1
18 11.08.2014VIJAYLAKSHMI S 44 2 28.5 874610F 0 1
19 11.08.2014AJOY NAND PATHAK63 1 26.1 883694F 0 2
20 11.08.2014KARTHIK 24 1 27.7 791237F 0 2
21 11.08.2014PARIMALA 32 2 22.5 882291F 0 2
22 11.08.2014SAKTI PADA ROY 61 1 22.1 502427D 2 1
23 12.08.2014INJAMAL HAQUE CHOWDHARY20 1 18.1 775697F 0 2
24 13.08.2014CHAKKINI PRIYA 20 2 18.7 795424F 0 1
25 14.08.2014ANAMIKA ROY 41 2 27.1 047734F 0 1
26 19.08.2014TAPAS KUMAR CHATTERJEE60 1 22.2 024113G 2 1
27 19.08.2014ARINDHAM BISWAS21 1 21.2 026413G 0 2
28 20.08.2014KUNTI DEVI 28 2 25.1 866366F 0 1
29 20.08.2014ECHAHAK KHALASI 46 1 20.1 023938D 0 2
30 26.08.2014SANATHAN BAURI 20 1 28.6 029333G 0 2
31 28.08.14 AVIJIT ANKURIA 27 1 20.4 881541F 0 2
32 29.08.2014FUZEIL AHAMED 43 1 20.1 693478F 0 1
33 02.09.2014MENOKA MONDAL 41 2 21.1 843763F 0 2
34 03.09.2014ARATAN SARDAR 37 2 23.5 031754G 0 1
35 03.09.2014TAPAS KUMAR 22 1 26.1 039762G 0 1
36 03.09.2014WONTHARLA SHIPO57 1 27.2 263941D 0 2
37 03.09.2014VICTOR DAYANANTHAM43 1 24.5 647060F 0 1
38 11.09.2014LITON KUMAR SAHA26 1 28.1 898067F 1 1
39 15.09.2014NIMA REGISOW 23 1 23.1 851904F 0 2
40 15.09.2014SEENUVASAN 29 1 28.7 018266G 0 1
41 18.09.2014MASSOD ALAM 40 1 21.7 839874F 0 2
42 18.09.2014CHANDANA DAS 53 2 25.3 433343F 0 1
43 26.09.2014WASIM ANSARI 21 1 19.3 056900G 0 1
44 26.09.2014RABIUL DHALI 28 1 21.9 046698G 0 2
45 06.10.2014RANJAN BABU 40 1 18.1 241228F 0 1
46 06.10.2014SANDHYA SARKAR 21 2 16.6 054827G 0 2
47 07.10.2014SADAF NAZ 28 2 15.8 867072F 0 1
48 10.10.2014BIBIN K V 32 1 21.7 003410G 0 1
49 10.10.2014MUTHU S 31 1 25.7 408888F 0 1
50 10.10.2014AFSAR UZZAMAN 36 1 20.2 039926G 0 2
51 15.10.2014SANJAY MANDAL 26 2 22.8 854205F 0 2
52 15.10.2014MALAY MONDAL 31 1 17.4 851429F 0 2
53 16.10.2014RATHIKA.J 32 2 23.4 456607D 0 2
54 16.10.2014BABY 29 1 29.6 057275G 0 1
55 21.10.2014MANGALA TUDUK 31 2 24.9 039597G 0 1
56 21.10.2014VIJAYAKUMAR.K 30 1 24.8 061522G 0 2
57 22.10.2014DIPALI SARKAR 37 2 23.7 010451G 0 2
58 22.10.2014ASHOK ROUL 27 1 22.1 065350G 0 2
59 27.10.2014UMA MONDAL 41 2 24.1 616124F 0 1
60 27.10.2014VASIHA.P. 21 2 20.8 950563A 0 1
61 27.10.2014SEIKH SAIFUDDIN 42 1 26.3 629613D 0 1
62 27.10.2014VENKATESAN 24 1 21.6 074132G 0 2
63 31.10.2014MUKESH BHATT 41 1 26.1 069768G 0 1
64 04.11.2014BIGUN CHOWDHURY28 2 22.5 068130G 0 2
65 10.11.2014DEV NARAYAN 36 1 28.9 050055G 0 2
66 12.11.2014SUBRATA BAGCHI 26 1 19.5 091294G 0 1
67 12.11.2014HEMANT KUMAR DAS29 1 21.3 091413G 0 2
68 12.11.2014RUBY DHARA 23 2 22.1 025688G 0 1
69 14.11.2014AMBIKA 26 2 22.3 531159D 0 1
70 14.11.2014VENKATESAN 36 1 17.6 068244G 0 2
71 14.11.2014HAKKIMA BEGUM 31 2 27.2 077724G 0 2
72 18.11.2014SIVAKUMAR C 21 1 18.2 054498G 0 2
73 22.11.2014DINESH KUMAR 52 1 24.4 321196F 1 1
74 22.11.2014GIRI 33 1 29.1 931334F 2 2
75 28.11.2014AJITH KUMAR 30 1 27.2 051207G 0 1
76 28.11.2014SUJAY ROY 31 1 20.1 088602G 0 2
77 02.12.2014ABADUR RAHMAN 32 1 25.5 098273G 0 2
78 04.12.2014REUMEGUE JOHN 23 2 19.1 027289G 0 2
79 10.12.2014AMIT KUMAR 25 1 24.5 087998G 0 1
80 12.12.2014AMBIGA N 27 2 18.8 077454G 0 1
81 15.12.2014DIVYA P 22 2 26.1 952435C 0 1
82 27.12.2014RAMALEWAR MAHATO42 1 28.7 937048F 0 2
83 27.12.2014MANIACKARAJ M 70 1 26.1 937171F 1 2
84 27.12.2014LEELAVATHY 25 2 22.6 984203D 0 2
85 27.12.2014BABU 63 1 29.1 936874F 0 1
86 28.12.2014NAGAIAH 50 1 28.7 936862F 2 1
87 28.12.2014MANJULA 48 2 27.3 008196F 0 2
88 28.12.2014THIRUVIKARMA REDDY42 1 23.2 104255G 0 1
89 28.12.2014SEIKINDER ALI DESAI55 1 24.9 081329G 0 1
90 02.01.2015DHANDAPANI 46 1 25.4 111609G 2 2
91 22.01.2015YUREKHA 20 2 25.5 095986B 0 1
92 22.01.2015JEYACHANDER 26 1 21.1 798202A 0 2
BASE LINE HEART RATEPREINTUBATION HR AT 1 MINUTEPREINTUBATION HR AT 2 MINUTEPOST TUBATION HR AT 1 MINUTEPOST I TUBATION HR AT 2 MINUTEPOST INT BATION HR AT 3 MINUTEPOST INT BATION HR AT 4 MINUTEPOST INT BATION HR AT 5 MINUTEB SE LINE SBP
88 94 95 90 89 91 92 96 103
88 80 80 84 90 86 82 83 172
83 86 88 72 86 93 90 96 140
97 84 84 86 88 86 90 88 131
105 78 69 80 81 76 70 72 119
77 70 64 62 64 70 70 72 136
111 95 95 91 94 87 91 78 151
77 77 81 82 82 86 81 79 122
78 79 69 69 67 78 79 68 147
106 111 96 102 97 84 81 84 152
92 90 92 90 92 88 85 86 130
80 72 80 88 78 73 68 64 107
74 66 80 80 79 90 92 95 120
95 88 88 78 93 95 99 94 134
84 93 88 111 112 113 109 112 128
98 81 79 95 92 81 83 82 141
80 61 84 89 95 83 79 66 121
78 76 74 87 89 87 86 85 108
91 93 89 94 92 93 95 97 126
80 79 86 94 87 91 84 80 171
120 117 106 103 112 122 110 108 145
84 73 83 74 84 92 85 88 88
79 85 104 104 103 95 90 89 153
60 63 68 91 85 82 81 75 136
70 90 89 106 100 101 97 93 133
123 115 104 102 120 117 116 111 146
69 58 60 96 87 83 71 69 127
101 66 66 70 87 85 80 82 122
96 88 99 81 83 82 81 81 176
78 70 81 77 89 88 76 75 113
90 87 78 89 87 87 81 80 133
75 79 79 78 101 98 100 89 138
69 57 60 74 69 67 67 66 126
71 58 55 81 72 63 60 58 131
65 73 90 86 93 87 87 83 109
95 95 90 102 90 88 89 93 173
78 95 89 89 90 91 91 90 133
70 82 86 88 91 94 97 99 127
71 61 76 76 84 82 75 78 124
79 81 79 115 105 106 102 89 147
70 69 72 101 99 92 109 101 123
95 87 80 107 108 79 81 78 140
77 84 81 89 84 82 78 77 111
66 73 71 115 113 115 108 102 101
91 75 75 83 101 100 100 97 144
61 61 53 93 103 98 100 90 116
121 75 93 98 91 90 80 78 109
86 74 75 92 94 89 90 92 121
92 72 68 80 81 84 80 75 123
72 80 88 93 90 89 87 86 111
102 85 81 62 86 84 82 82 138
70 80 82 74 79 76 72 71 130
79 68 79 91 95 96 92 88 180
93 96 84 84 93 94 98 94 163
79 71 75 84 82 98 95 93 109
92 85 84 74 87 85 79 76 156
84 89 88 87 88 84 78 81 129
79 73 71 91 96 91 80 72 119
75 77 87 77 82 87 95 99 117
71 65 64 92 97 100 98 90 167
83 83 83 87 101 99 97 92 140
64 72 79 81 68 69 70 72 140
81 83 71 88 83 109 106 104 135
91 98 91 99 94 98 95 99 122
118 100 96 98 94 91 90 90 123
72 67 69 68 93 96 96 102 119
85 80 76 96 100 90 83 97 110
106 100 102 115 92 132 127 117 175
66 65 81 82 88 105 99 88 133
68 66 67 68 69 78 84 63 154
83 83 79 92 88 88 87 88 145
68 84 65 76 98 92 102 88 130
73 101 106 76 83 79 79 83 106
77 86 79 97 98 89 98 85 118
78 90 76 99 89 102 101 95 116
87 100 92 74 106 105 107 102 124
71 66 59 74 80 74 83 71 103
91 81 77 91 93 84 86 80 102
76 70 68 82 80 80 86 78 132
92 88 96 110 120 116 118 102 140
92 80 86 102 98 104 106 104 140
88 80 69 72 76 76 74 78 132
110 102 100 112 102 102 100 82 140
76 76 70 84 82 82 80 86 110
108 100 92 98 106 108 106 102 130
76 100 102 110 102 108 116 104 140
68 70 76 78 80 76 72 72 110
84 101 103 110 107 109 101 101 157
84 82 84 105 103 97 92 88 131
BASELINE DBPPREINTUBATION SBP AT 1 MINUTEPREINTUB ION DBP AT 1 MINUTEPREINTUBATION SBP AT 2 MINUTEPREINTUB ION DBP AT 2 MINUTEPOSTINT BATION SBP AT 1 MINUTEPOSTINT B ION DBP AT 1 MINUTEPOSTINTUBATION SBP AT 2 MINUTEPOSTINTUB ION DBP AT 2 MINUTE
67 115 78 113 74 75 40 72 38
96 176 100 167 96 150 93 134 77
88 111 63 110 50 76 39 98 69
82 107 79 96 72 88 62 84 60
64 92 54 88 55 95 52 90 45
79 86 58 80 52 82 52 94 66
99 140 100 144 120 155 100 156 98
65 117 70 70 50 128 88 125 84
82 138 83 128 76 116 72 113 73
73 166 88 155 77 134 74 132 70
72 128 70 128 74 130 70 128 68
68 84 54 96 71 104 70 93 63
73 106 68 95 62 92 61 83 54
78 112 71 103 65 121 89 132 91
72 114 72 129 80 116 71 110 64
96 118 80 110 76 148 100 134 93
78 111 75 115 75 161 100 156 110
66 103 59 102 62 114 66 112 65
74 90 50 94 54 118 70 100 57
88 163 89 145 99 172 110 143 84
83 79 46 82 40 109 65 125 78
58 88 57 73 46 106 81 116 83
100 111 79 132 74 106 71 146 102
81 97 68 90 63 133 100 146 104
84 112 72 105 65 127 84 121 78
98 134 91 138 91 99 64 124 89
81 107 71 95 61 162 112 143 83
80 94 47 101 51 116 71 104 57
104 155 95 159 101 115 61 116 68
75 106 71 119 76 96 72 121 83
86 98 60 75 51 82 60 104 71
83 123 82 122 79 110 81 137 87
83 124 81 103 57 124 67 99 57
77 75 47 77 51 147 92 130 88
75 78 51 71 46 126 87 126 92
108 162 111 131 81 144 96 125 76
83 116 71 117 71 109 63 127 89
73 138 86 131 70 144 85 147 90
78 86 58 88 61 103 66 104 72
83 89 50 98 60 156 112 159 101
72 124 73 118 74 94 54 94 56
87 81 47 85 45 120 78 123 79
77 93 63 91 60 97 67 93 63
65 91 55 88 55 123 87 114 78
77 116 66 110 59 119 80 130 80
72 116 69 135 64 102 67 137 96
52 128 84 106 68 113 87 126 85
69 104 60 95 60 135 90 132 85
79 109 61 96 53 133 83 128 77
81 102 67 108 72 96 63 92 55
91 109 69 112 71 120 85 137 84
87 106 72 132 86 91 60 87 56
105 108 64 116 81 153 94 145 96
71 126 75 89 58 153 94 156 83
59 105 65 108 66 116 70 120 68
88 123 78 136 78 107 73 129 83
73 86 49 86 49 105 70 98 59
68 99 63 91 56 136 89 158 108
81 89 55 97 62 95 58 110 77
117 167 109 159 115 177 116 175 114
75 134 87 113 73 124 78 131 88
90 150 94 152 92 154 88 130 80
81 121 72 118 80 101 64 96 55
81 119 82 108 71 138 97 135 95
80 111 73 100 62 98 63 97 61
74 111 69 107 68 108 69 98 60
72 112 76 119 69 95 61 117 88
102 148 107 151 91 100 54 102 60
82 129 89 146 96 118 83 118 84
100 156 99 154 105 105 70 105 52
74 109 57 96 55 128 73 114 60
78 133 83 139 87 109 62 105 63
68 92 57 105 69 95 59 119 77
73 114 77 109 75 129 99 146 109
69 116 65 114 81 119 70 127 71
77 106 63 105 58 126 86 149 100
65 96 63 97 62 100 56 86 48
62 106 66 129 73 103 59 93 51
74 110 60 102 66 128 62 140 70
88 100 60 98 64 128 76 144 86
84 110 70 108 74 146 82 146 84
80 110 70 118 70 128 68 124 70
98 120 76 110 80 117 80 114 82
70 120 60 100 60 128 62 130 70
80 100 58 102 62 120 80 124 72
87 146 88 130 80 136 84 128 88
70 94 62 88 60 110 70 110 62
107 128 87 128 76 135 92 123 87
81 100 63 97 57 128 86 114 74
POSTINTUBATION SBP AT 3 MINUTEPOSTINTUB ION DBP AT 3 MINUTEPOSTINTUBATION SBP AT 4 MINUTEPOSTINTUB ION DBP AT 4 MINUTEPOSTINTUBATION SBP AT 5 MINUTEPOSTINTUB ION DBP AT 5 MINUTEBASE LINE MAPAP PREIN UBATION MINUTE 1MAP PREINTUBA ION 2 MINUTE
79 50 89 63 91 57 79 90 87
136 70 133 70 126 65 121 125 119
97 67 127 61 99 60 105 79 70
84 60 91 56 95 58 98 88 80
94 55 96 50 98 50 82 67 66
100 57 93 69 88 60 98 67 61
105 74 107 72 136 96 116 113 128
115 73 102 73 98 66 85 85 56
131 82 113 60 102 59 103 101 92
118 67 105 56 134 91 99 114 103
126 74 126 72 124 72 91 89 91
87 54 80 50 80 52 81 64 79
92 56 120 80 110 71 88 80 73
120 81 124 80 124 77 97 85 78
109 58 107 59 105 59 91 86 96
114 77 109 75 115 84 111 93 87
154 95 132 77 121 71 92 87 83
110 59 108 59 106 57 80 74 75
100 50 94 50 92 52 91 63 67
157 96 147 82 124 76 116 122 114
127 70 124 72 128 70 104 57 54
130 82 101 69 81 53 68 67 55
130 87 119 80 116 68 118 90 93
136 94 133 90 122 79 99 78 72
113 69 110 64 107 58 100 85 78
115 70 120 62 95 55 114 105 107
130 88 97 65 100 65 96 83 72
97 61 97 49 97 49 94 63 68
119 67 116 64 118 65 128 115 120
108 72 103 64 98 60 88 83 90
91 62 87 59 84 56 102 73 59
122 77 131 78 111 67 101 96 93
97 48 90 47 93 48 97 95 72
105 70 98 61 85 54 95 56 60
106 71 101 69 97 65 86 60 54
125 78 121 72 124 74 130 117 98
117 71 139 75 117 66 100 86 86
150 96 159 96 161 104 91 103 90
99 64 86 54 86 50 93 67 70
143 104 155 110 140 92 104 69 73
92 56 108 72 117 68 89 90 89
110 70 124 64 101 57 105 58 58
91 60 90 58 87 58 88 73 70
115 78 100 67 96 59 77 67 66
119 74 120 65 113 60 99 83 76
138 92 122 70 105 60 87 85 88
116 79 98 65 96 60 71 99 81
131 83 125 81 118 67 86 75 72
107 63 92 46 86 44 94 77 67
91 56 90 56 90 55 91 75 84
120 75 113 67 114 70 107 82 85
83 52 84 51 83 53 103 83 101
152 91 141 88 146 81 130 79 93
125 70 130 69 122 70 102 92 68
104 66 110 62 120 64 76 78 80
107 75 94 60 87 55 111 93 97
92 54 95 54 93 53 92 61 61
134 85 118 77 113 79 85 75 68
127 91 122 87 121 80 93 66 74
152 104 150 100 146 96 134 128 130
137 91 132 84 114 68 97 103 86
132 72 118 64 116 60 107 113 112
153 113 154 105 145 75 99 88 93
130 89 129 87 111 70 95 94 83
91 56 91 55 91 54 94 86 75
94 60 98 64 106 68 89 83 81
122 81 107 70 98 64 85 88 86
107 60 104 56 96 56 128 121 111
133 86 121 85 118 75 99 102 113
99 68 107 79 87 52 118 118 121
124 70 105 62 104 54 98 74 67
144 102 142 100 138 97 95 100 104
100 65 93 59 103 69 81 69 81
128 86 140 97 123 77 88 89 86
121 66 119 71 110 65 85 82 92
131 80 124 82 114 71 93 77 74
84 47 111 82 100 80 78 74 74
91 51 92 48 100 60 75 79 92
136 80 116 70 120 66 93 77 78
150 88 156 82 150 83 105 73 75
130 78 148 80 136 72 103 83 85
130 72 136 72 132 68 97 83 86
118 80 128 76 120 74 112 91 90
110 72 110 72 100 70 83 80 73
136 88 128 84 121 82 97 72 75
142 86 150 84 144 76 105 107 97
118 66 124 70 112 68 83 73 69
122 82 108 69 108 69 123 100 93
105 67 100 60 91 52 98 75 70
MAP POSTINTUBATION 1 MINUTEMAP POSTINTUBATION 2 MINUTEMAP POS INTUBATION 3 MINUTEMAP POS INTUBATION 4 MINUTEMAP POS INTUBATION 5 MINUTEPRE INT BATION TACHYCARDIA 0 = NO , 1 = YESPREI T BATION BR DYCARDIA 0 = NO , 1 = YESPREINTUBATION HYPOTENSION 0 = NO , 1= YESPREINTUBA ION HYPERTENSION 0 = NO , 1 = YES.
52 49 60 72 68 0 0 0 0
112 96 92 91 85 0 0 0 0
51 79 77 83 73 0 0 1 0
70 68 68 67 70 0 0 0 0
66 60 68 65 66 0 1 0 0
62 75 71 77 69 0 0 1 0
118 119 84 83 109 0 0 0 0
101 97 87 82 76 0 0 1 0
87 86 98 78 73 0 0 0 0
94 90 84 69 105 0 0 0 0
90 88 91 90 89 0 0 0 0
81 73 65 60 61 0 0 0 0
71 64 68 93 84 0 0 0 0
100 105 94 95 93 0 0 0 0
86 79 75 75 74 0 0 0 0
116 107 89 86 94 0 0 0 0
120 125 114 95 88 0 1 0 0
82 81 76 75 73 0 0 0 0
86 71 67 65 65 0 0 1 0
131 104 116 104 92 0 0 0 0
80 94 89 89 89 0 0 1 0
89 94 94 80 61 0 0 0 0
83 117 101 93 84 0 0 1 0
111 118 109 104 93 0 0 1 0
98 92 83 79 74 1 0 1 0
76 101 85 81 68 0 0 0 0
129 103 102 76 77 0 0 1 0
86 73 73 65 65 0 1 1 0
79 84 84 81 83 0 0 0 0
80 96 84 77 73 0 0 0 0
67 82 72 68 63 0 0 1 0
91 104 92 96 82 0 0 0 0
86 71 64 61 63 0 0 1 0
110 102 82 73 64 0 1 1 0
100 103 82 80 76 1 0 1 0
112 92 93 88 91 0 0 0 0
78 102 86 96 83 1 0 0 0
105 109 114 117 123 1 0 0 0
78 83 76 65 62 0 0 1 0
127 117 117 125 108 0 0 1 0
67 69 68 84 84 0 0 0 0
92 94 83 84 72 0 0 1 0
77 73 70 69 68 0 0 0 0
99 90 90 78 71 0 0 0 0
93 97 89 83 77 0 0 1 0
79 110 107 87 75 0 0 0 0
96 97 91 76 72 0 1 0 1
105 101 99 96 84 0 0 0 0
100 94 78 61 58 0 1 1 0
74 67 68 67 67 1 0 0 0
97 102 90 82 85 0 0 1 0
70 66 62 62 63 0 0 0 0
114 112 111 106 103 0 0 1 0
114 107 88 89 87 0 0 1 0
85 85 79 78 83 0 0 0 0
84 98 86 71 66 0 0 0 0
82 72 67 68 66 0 0 1 0
105 125 101 91 90 0 0 0 0
70 88 103 99 94 0 0 1 0
136 134 120 117 113 0 0 0 0
93 103 106 100 83 0 0 0 0
110 97 92 82 79 1 0 0 0
76 69 126 121 98 0 0 0 0
111 108 103 101 84 0 0 0 0
75 73 66 67 66 0 0 0 0
82 73 71 75 81 0 0 0 0
72 98 95 82 75 0 0 0 0
69 74 76 72 69 0 0 0 0
95 95 102 97 89 1 0 0 0
82 70 78 88 64 0 0 0 0
91 78 88 76 71 0 0 1 0
78 77 116 114 111 1 0 0 0
71 91 77 70 80 1 0 0 0
109 121 100 111 92 0 0 0 0
86 90 84 87 80 0 0 0 0
99 116 97 96 85 0 0 0 0
71 61 59 92 87 0 0 0 0
74 65 64 63 73 1 0 0 0
84 93 99 85 84 0 0 0 0
93 105 109 107 105 0 0 1 0
103 105 95 103 93 0 0 0 0
88 88 91 93 89 0 0 0 0
92 93 93 93 89 0 0 0 0
84 90 85 85 80 0 0 0 0
93 89 104 99 95 0 0 1 0
101 101 105 106 99 1 0 0 0
83 78 83 88 83 0 0 0 0
106 99 95 82 82 1 0 1 0
100 87 80 73 65 0 0 1 0
MANAGEMENT OF PREINUBATION RESPONSE: 0=NONE; 1=ATROPINE; 2=EPHEDRINE; 3=PNP; 4= FENTANYL; 5=PROPOFOL; 6= OTHER DRUGSPOST INTUBATION TACHYCARDIA 0 = 0 , 1 = YESPOST IN UBATION BRADYCARDIA 0  N0 , 1 = YESPOST INTUBATION HYPOTENSION 0 = NO , 1 = YESPOST INTUBA ION HYP RTENSION 0= NO , 1 = YESMA AGEMEN  OF P ST I TUBATION RESPONSE: 0=NONE; 1=ATROPINE; 2=EPHEDRINE; 3=PNP; 4= FENTANYL; 5=PROPOFOL; 6= OTHER DRUGS
0 0 0 1 0 3
0 0 0 1 0 0
0 0 0 1 0 0
0 0 0 1 0 0
0 0 1 1 0 0
0 0 0 1 0 0
0 0 1 1 0 0
0 0 0 0 0 0
0 0 0 1 0 0
0 0 1 1 0 0
0 0 0 0 0 0
0 0 0 1 0 0
0 1 0 0 0 0
0 0 0 0 0 0
0 1 0 0 0 0
0 0 0 1 0 0
0 0 0 0 1 0
0 0 0 0 0 0
0 0 0 1 0 0
0 0 0 1 0 0
0 0 0 1 0 0
3 0 0 0 1 0
0 1 0 1 0 0
0 1 0 0 0 0
0 1 0 0 0 0
0 0 0 1 0 0
0 1 0 1 1 0
0 0 1 1 0 0
0 0 0 1 0 0
0 0 0 0 0 0
0 0 0 1 0 0
0 1 0 0 0 0
0 0 0 1 0 0
0 0 0 1 0 0
0 1 0 0 0 0
0 0 0 1 0 0
0 0 0 1 0 0
0 1 0 0 1 0
0 0 0 1 0 0
0 1 0 0 1 0
0 1 0 1 0 0
2 0 0 1 0 0
0 0 0 1 0 0
0 1 0 0 1 0
0 0 0 1 0 0
0 1 0 0 1 0
0 0 1 0 1 0
0 1 0 0 0 0
0 0 0 1 0 0
0 1 0 1 0 0
0 0 1 1 0 0
0 0 0 1 0 0
0 1 0 1 0 0
0 0 0 0 0 0
0 1 0 0 0 0
0 0 0 1 0 0
0 0 0 1 0 0
0 1 0 0 1 0
0 1 0 1 0 0
0 1 0 0 0 0
0 1 0 0 0 0
0 1 0 1 0 0
0 1 0 1 0 0
0 0 0 0 0 0
0 0 1 1 0 0
0 1 0 0 0 0
0 0 0 0 0 0
0 0 0 1 0 0
0 1 0 0 0 0
0 1 0 1 0 0
0 0 0 0 0 0
0 1 0 0 0 0
0 0 0 0 0 0
0 1 0 0 1 0
0 1 0 0 0 0
0 1 0 0 1 0
0 0 0 1 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 1 1 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 1 0 0 0 0
0 0 0 0 0 0
0 1 0 1 0 0
0 1 0 1 0 0
MANAGEMENT OF POST INTUBATION RESPONSE: 0=NONE; 1=ATROPINE; 2=EPHEDRINE; 3=PNP; 4= FENTANYL; 5=PROPOFOL; 6= OTHER DRUGS
